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Independent Auditors' Report: CIAT Proprietary Property 
1 am pleased to send you the completed Audit of CIA T's proprietary property 
management, comprising intellectual property (IP) and technical property and 
information (TP), and the in-depth review of selected projects. 
The Audit was designed to focus on selected parts of CIA T's activities and existing 
agreements and contracts related to IP/TP management as a way of providing a 
pragmatic basis for CIAT's future policy towards and management ofiP/TP. To this 
effect, we also undertook a detailed paralegal freedom-to-operate review of a major 
project to illustrate the processes and highlight the complexities of current IP/TP issues. 
The Audit was conducted by a team of professionals in various aspects related to 
IP/TPmanagement, contractual issues, institutional strategies and biotechnology, 
including an ISAAA retained attomey and severa! consultants for advice on specialized 
topics. 
Nevertheless, the accompanying report excludes legal opinions, including but not 
limitedto freedom-to-operate opinions or opinions regarding the patentability of 
germplasm or any technology or invention. 
Conducted from April to October 2000, the Audit consisted of a visit to CIA T by severa! 
members of the team, the review of critica! documentation, and detailed discussions in 
person and by other means with a variety ofCIAT staffand management. We relied on 
CIA T to compile and supply us with those agreements, related documents, and 
information that they have in force, whose terms included proprietary property related 
obligations and rights, and found the documentation from CIA T staff members to be 
timely, detailed, and comprehensive. We have been given free access to all necessary 
documentation and related information as we ll as to CIA T staff at alllevels and 
functions. 
During our Audit, we applied standards and interpretations of facts and statements that 
wou ld generally be applied with the same rigor by proprietary property managers 
servicing pub lic or private sector entities in a range of industrialized countries, 
particularly the USA, where statutory protection is well established. As a consequence, 
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we placed special emphasis on policies, strategies and management practices related to 
the inflow to CIA T of IP and TP; to the outflow from CIA T of IP and TP; and to the 
interna! handling and use of IP and TP. 
You will find a detailed analysis of your institute' s current policies, procedures and 
agreements, and selected projects that have IP and TP components. We list the major 
findings in the Executive Summary and provide you with approximately 30 detailed 
recommendations to point out areas where CIAT may wish to strengthen or harmonize 
its overall policies and procedures. Certain recommendations are directly related to the 
projects we analyzed; the rel evant department or project leaders may wish to follow-up 
on these in the near term. Finally, we discuss the findings and recommendations from 
the perspective of germplasm management, central management, agreements 
management, biotech component management, biotech product management, freedom-
to-operate management, strategic risk management, and electronic data management. 
Our major conclusions are: 
l . During the Audit, we found no matter that violated or vio lates CIA T's Board 
approved policies, or current practices of the not-for-profit and educational research and 
development communities for intemational agriculture. 
2. We are confident that no Audited activity, agreement, or policy and procedure of 
CIA T constitutes any impropriety. 
3. The Audit demonstrated to us that CIAT management and staffare well aware ofthe 
challenges facing CIA T as it relates to IP and TP management, with an eagemess to 
build upon the institute's existing capacity in these areas. 
4. We are certain that our in-depth analysis ofseveral projects, particularly the freedom-
to-operate review, will serve your objectives of establishing rational policies, consistent 
strategies and predictable management systems as they relate to IP and TP. 
5. We are encouraging CIAT to move swiftly with a revision ofits overall IP/TP policies 
once senior management and possibly the Board ofTrustee have hadan opportunity to 
review our detailed recornmendations. 
6. The above noted need for the harmonization of CIA T's policies and procedures with 
systematic and predictable IP/TP rights management practices is not without cost, either 
financia! or política!. However, fai lu re todo so wi ll, in the long term, adversely affect 
CIA T's relationship with its staff, its clients, its donors and non-CIA T collaborators. 
7. A large number of recommendations are directly related to the projects we analyzed 
and we strongly encourage that the relevant department or project leaders follow-up on 
these in the near term. 
8. The Audit, which included a detailed analys is of a limited number of CIA T projects, 
should be taken only as a starting point for continuing reviews of IP/TP issues by CIA T 
staff, management and Board ofTrustees. As the Audit report is integrated into CIA T's 
on-going activities, CIA T managers and staff members should be in a good position to 
have the in-house capacity to deal with the current recommended changes as well as 
proactively handle future IP/TP issues as they arise. 
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9. CIAT will then be in a good position to institutionalize fonnal and predictable IP and 
TP management procedures in a timely and effective manner. This will go a long way 
towards ensuring CIA T's effective operations in the future by allowing it to capitalize on 
IPffP of others for the benefit of its clients. 
In conclusion, allow me to stress that CIA T should neither fear nor fixate on the 
complexities of these issues. The management of proprietary property is nothing but a 
tool that, used wisely, will increase CIAT's efficiency and opportunities. 
It is with pleasure that I acknowledge the contribution of a number of ISAAA staff, 
particularly Dr. Stanley Kowalski, ISAAA Intems in IPrrP Management, speci.fically 
Dr. Tantono Subagyo, and Dr. Reynaldo Ebora, and Dr. John Dodds ofDodds & 
Associates (ISAAA retained attomey), Donna Bobrowicz (consulting attomey) and Dr. 
Anatole F. Krattiger (intemational consultant, bioDevelopments LLC), for their 
dedicated hard work during the entire Audit and for their valuable contributions and 
advice. 
I would also like to thank CIAT's management and stafffor the excellent cooperation 
during the entire Audit and personally wish you and your institute every success in 
VP1Y~u;:mission. 
R. David Kryder 
Director 
Global IP/TT Initiative, ISAAA 
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DISCLAIMER 
The present document, while it contains information on ownership and statutory 
intellectual property rights issues, excludes legal opinions, including but not limited to 
freedom-to-operate opinions or opinions regarding the patentability of germplasm or any 





An extemal Audit of selected procedures and projects at CIA T in regard to the management of 
Proprietary Property (PP, comprising intellectual property and technical property [IP!TP]), was 
conducted with emphasis on biotechnology-related activities and components, information 
management and germplasm movement, and an analysis of CIA T' s management of the 
components. During the Audit, standards and interpretations of facts and statements were applied 
that would generally be applied with the same rigor by practitioners servicing public or private 
entities in industrialized countries. 
The Audit was designed to focus on selected parts of CIA T's activities and existing agreements 
and contracts related to IP!TP and information management as a way of providing a pragmatic 
basis for CIA T's future policy towards and management of IP!TP and information. To this effect, 
we also undertook a detailed freedom-to-operate review of a major project to illustrate the 
processes and highlight the complexities of current IP!TP issues. 
The Audit was conducted by a team of professionals in various aspects related to IP!TP 
management, contractual issues, institutional strategies and biotechnology, including an ISAAA 
retained attomey and several consultants for advice on specialized topics. Nevertheless, the 
accompanying report excludes legal opinions, including but not limited to freedom-to-operate 
opinions or opinions regarding the patentability of germplasm or any technology or invention. 
Conducted from April to October 2000, the Audit consisted of a visit to CIA T by three members 
ofthe team, the review of critical documentation, and detailed discussions in person and by other 
means with a variety of CIA T staff and management. We relied on CIA T to compile and supply 
us with those agreements, related documents, and information that they have in force, whose 
terms included proprietary property related obligations and rights, and found the documentation 
from CIAT staffmembers to be timely, detailed, and comprehensive. We have been given free 
access to all necessary docurnentation and related information as well as to CIA T staff at all 
levels and functions. 
Specific areas and questions considered for the projects and agreements included, among others: 
• whether the purposes ofthe agreements were consistent with CIA T's stated institutional 
goals and objectives and in line with its status asan intemational organization; 
• whether the strategies resulting from the obligations under the agreements to reach these 
objectives were consistent with CIAT's stated policies; 
• whether key personnel were sufficiently knowledgeable about the obligations embedded in 
agreements to adhere to the intents that led to specific agreements; 
• whether there are conflicts in research partnerships with non-CIA T partners regarding the use 
ofCIAT-housed germplasm (e.g. , Designated vs. Non-Designated) that may conflict with 
other CIAT - non-CIAT agreements (such as confidentiality); 
• whether clear and consistent procedures are in place to implement and manage the 




The major conclusions ofthe Auditare as follows : 
l. During the Audit, we found no matter that violated or violates CIAT's Board approved 
policies, or current practices ofthe not-for-profit and educational research and development 
communities for intemational agriculture. 
2. We are confident that no Audited activity, agreement, or policy and procedure ofCIAT 
constitutes any impropriety. 
3. The A u di t demonstrated to us that CIA T management and staff are well aware of the 
challenges facing CIAT as it relates to IPffP and information management, with an 
eagemess to build upon the institute's existing capacity in these areas. 
4. We are certain that our in-depth analysis of several projects, particularly the freedom-to-
operate review, will serve your objectives of establishing rational policies, consistent 
strategies and predictable management systems as they relate to IPrrP and information. 
5. We are encouraging CIAT to move swiftly with a revision ofits overall IPffP policies once 
senior management and possibly the Board ofTrustee have hadan opportunity to review our 
detailed recommendations. 
6. The above noted need for the harmonization ofCIAT's policies and procedures with 
systematic and predictable PP rights management practices is not without cost, either 
financial or political. However, failure to do so will, in the long term, adversely affect 
CIA T 's relationship with its staff, its clients, its donors and non-CIA T collaborators. 
7. A large nurnber ofrecommendations are directly related to the projects we analyzed and 
strongly encourage that the relevant department or project leaders follow-up on these in the 
near term. 
8. The Audit, which included a detailed analysis of a limited nurnber of CIA T projects, should 
be taken only as a starting point for continuing reviews ofiPffP issues by CIAT staff, 
management and Board ofTrustees. As the Audit report is integrated into CIAT's on-going 
activities, CIA T managers and staff members should be in a good position to ha ve the in-
house capacity to deal with the current recommended changes as well as proactively handle 
future IPrrP issues as they arise. 
9. CIAT will then be in a good position to institutionalize formal and predictable IPffP and 
information management procedures in a timely and effective manner. This will go a long 
way towards ensuring CIAT's effective operations in the future by allowing it to capitalize 
on IP, TP and information of others for the benefit of its clients. 
Specific Recommendations derived from the Analysis of Projects 
Three current projects were analyzed in detail. These are: 
• Product Clearance Review of Rice Hoja Blanca Virus Resistant Transgenic Rice 
This deconstruction of a near-term product illustrated the process and highlighted the 
complexities and possible implications for CIA T in seeking to regularize its activities. CIA T will 
find itself in a position to consider the risks and rewards of not obtaining any further agreements 
for the components specified in a Product Clearance Spreadsheet prepared by the Auditors vs. 
iv 
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obtaining commerciallicenses/agreements for each ofthe components vs. reconstructing the 
en tire construct. Decisions regarding these approaches, or variants of them, may determine 
CIAT's success with the rice product and will have wider implications for other projects, 
specifically for NARS. 
The project analysis led to seven recommendations related to the handling ofiP, TP and related 
information, namely: 
Recommendation 2: CIAT should institute a laboratory notebook protocol, particularly in 
electronic form (note that we included a special sub-section with a 
proposed policy for consideration by CIAT) 
Recommendation 3: Setting-up of a Database and related management practices concerning the 
release of germplasm 
Recommendation 4: Product Clearance Spreadsheet and FTO Information 
Recommendation 5: Agreement management procedures 
Recommendation 6: CIA T should clearly define its needs when negotiating and entering into 
MT As with non-CIA T parties 
Recommendation 7: Consider the establishment of an Office of General Counsel 
Recommendation 8: Review and revise CIAT's standard MTA 
Furthermore: 
Recommendation 1: It might be worthwhile for CIAT to explore the patentability ofCIAT's 
developed transformation system using immature panicles as this 
technique is being further developed. It appears that it involves innovative 
steps that are not yet fully covered by patents. 
• Brachiaria 
The analysis ofthis project centered around the complex area ofmovement of germplasm and 
terms under which germplasm moved to CIAT, within CIAT and to its clients, as well asto its 
collaborators (particularly the prívate sector). The major conclusions from this analysis are the 
following recommendations: 
Recommendation 9: CIAT should designate a person responsible for monitoring developments 
under the CBD and F AO regarding F AO-designations 
Recommendation 10: Review and possibly re-negotiate the agreement with Semillas Papalotla 
Recommendation 11 : Monitor and document the source of all germplasm used in breeding 
programs 
Recommendation 12: Establish clear policies on negotiation with non-CIAT parties to ensure 
consistency and compliance 
Recommendation 13: Set in place a strategic response plan in the event that contract violations 
are alleged 
Recommendation 14: Institute a coordinated policy for germplasm movement between GRU and 
other CIAT units 
V 
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• FloraMap™ : A Tool for the Conservation ofGenetic Resources 
A detailed analysis ofthe development ofFLoraMap™ led to the following recommendations: 
Recommendation 15: CIA T should establish procedures for internally sharing essential research 
data 
Recommendation 16: CIA T should establish procedures for receiving and sharing data from 
non-CIA T parties 
Recommendation 17: CIAT should study the possible implication ofselling products (such as 
FloraMap™ or seeds) on its tax-exempt 501 (c)(3) status. 
Recommendation 18: CIAT should re-negotiate the agreement with ESRI or develop an 
alternative strategy 
Recommendation 19: Future version ofthe FloraMap™ Manuals should be revised to include 
appropriate references to ESRI software 
Recommendation 20: Harmonize distribution ofFloraMap™ with CIAT's policy or adapt 
CIAT's policies to its current practices 
Recommendation 21: CIAT should fully trademark the word ''FloraMap" together with the 
corresponding logo to prevent being blocked from use by a non-CIA T 
party 
Recommendation 22: CIAT should ensure that the type drawing trademark of"FloraMap" is in 
CIAT's name rather than in the name of one ofits former Director General 
Recommendation 23: CIA T should consult with its attorney and study the pros and cons of 
registering the copyright ofFloraMap™ in countries where the product 
has potential value 
Recommendation 24: CIAT should consider changing the licensing terms ofFloraMap™ 
Recommendations based on an Analysis of CIAT's Current IPITP Management Practices 
A detailed discussion on the implications ofthe Audit findings is presented in Section 3 ofthe 
report. In essence, it is apparent that CIAT, at alllevels, is doing a commendable job with the 
unnerving task of functioning under the new and evolving rules that are coming into play. Staff 
members, whether in support areas, management functions or in research were universally 
concerned to learn more about PP rights management. Throughout the organization there is a 
general spirit ofwillingness to "leam the new rules" in order to continue to move CIA T, in more 
efficient ways, toward its goal, and even to capitalize on these changes in a constructive manner. 
Certain areas where CIA T is harmonizing its interna! policies with changing PP rights 
management realities are noted and discussed. These include: 
• The Audit: Policy, Management and Procedural Implications 
Recommendation 25: CIAT should institutionalize a central IPfl'P management office to 
oversee all aspects of in-licensing and out-licensing 
Recommendation 26: CIA T should establish formal interna! procedures for the handling of 
all aspects related to IPfl'P management 
Recommendation 27: CIAT should offer IPfl'P management training to its staff 
vi 
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Recommendation 28: Following CIAT's analysis ofthe Audit, the Center should conducta 
comprehensive review of all of its policies related to IP to ensure 
harmonization and consistency. 
• Germplasm Management 
Recommendation 29: CIAT should review its policies and procedures related to the use and 
transfer of germplasm, and to the management of information derived 
thereof 
• Central Management 
Recommendation 30: CIAT should formalize its various procedures affecting IPffP 
management, ranging from confidentiality to staff and client training 
• Agreements Management 
Recommendation 31: CIAT should harmonize its policies and procedures, and formalize its 
management, of its agreements 
• Biotech Component Management 
Recommendation 32: CIAT should ensure that certain terms used in agreements are clearly 
de:fined and that the implications of standard definitions are properly 
understood 
• Biotechnology Product Management 
Recommendation 33: CIAT must consider the implications ofvarious options related to 
Freedom-To-Operate and should establish and communicate its 
position and mode of operation 
• Electronic Data Management 
Recommendation 16: CIAT should establish procedures for receiving and sharing data from 
· non-CIAT parties 
Conclusion 
It cannot be over-emphasized that CIA T should neither fear nor fixate on the complexities of 
these issues. The management ofproprietary property is nothing but a tool that, used wisely, will 
increase CIAT's efficiency and opportunities. 
CIAT's goal is not now and has never been in doubt. Effective IPffP management has the 
poten ti al to malee its endeavors more effective. In a certain way, CIA T has no option but to deal 
with the IP issues since the rules ha ve changed. The challenge for CIA T now is to continue on its 
path and reinforce its measures and activities to change, to better understand the new rules, and 
to capitalize on them for the benefit of the resource poor farmers it serves. 
vii 
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Germplasm Resources Unit 
Intemational Agricultura} Research Center 
Intemational Food Policy Research Institute 
Integrated Information Management Laboratory 
Intellectual Property 
Intemational Plant Genetic Resources Institute 
Intemational Rice Research Institute 
Intemational Service for the Acquisition of Agri-biotech Applications 
Material Transfer Agreement 
Nucleoprotein gene of RHBV 












Polymerase Chain Reaction 
Patent Cooperation Treaty 
Proprietary Property ( comprising IP and TP) 
Rice hoja blanca virus 
Read Only Memory 
SAMMDAT A South American Monthly Meteorological Data 
SGRP CGIAR System-Wide Information Network for Genetic Resources 
TFP Tropical Forages Program 








Trade-Related Aspects oflntellectual Property 
The Intemational Union for the Protection ofNew Varieties ofPlants 
Union Intemationale pour la Protection des Obtentions Vegetales 
United States Agency for Intemational Development 
United States Geological Survey 
W orld Intellectual Property Organization 
W orld Health Organization 




1. BACKGROUND ANO INTRODUCTION 
1.1 Proprietary Property Management at CIAT 
Since its inception in October of 1973, the Centro Internacional de Agricultura Tropical (CIA T) 
has been an advocate for the poor in developing countries. Its focus was initially on Latín 
Arnerica, but has subsequently broadened to in elude other regions. A main strength of CIA T has 
been its ability to freely receive and distribute improved germplasm and related information, 
ranging from agronomic knowledge to plant breeding systems. In fact, this free flow ofmaterial 
and related information has been used by many ofCIAT's funding sources as a performance 
measure. Understandably, CIA T staff and scientists-as well as the system of the Consultative 
Group on Intemational Agricultura} Research (CGIAR) as a whole-place a high value on the 
free exchange ofinformation and material. 
With the rapid expansion ofbiotechnology into the plant world, particular! y since the early-
1990s, it became apparent that this open approach was not sustainable if CIA T wanted to ensure 
that its clients continued to have access to the best germplasm incorporating the most valuable 
advances in science and technology. As increasing discoveries were made by the public sector in 
industrialized countries and with huge R&D investments by the private sector (both ofwhich led 
to many patents in plant biotechnology), much ofthe technology was no longer freely available 
to CIAT. Furthermore, many ofthe new breeding and information technologies now 
commonplace in industrialized countries are out of the reach of CIA T because of the high 
investment requirement which is simply not available to the intemational agricultura} research 
centers at times of declining budgets. (A single ag-biotech company in the USA, for example, 
may annually invest more into plant biotechnology R&D, including genomics, than the entire 
budget ofthe CGIAR system!). 
What has been a traditional partner in research for the CGIAR- the universities-have also 
become constrained by funding and IP. The university community has also become more and 
more secretive about their research projects and very often is seeking intellectual property (IP) 
protection on their discoveries. Statutory protection became commonplace as institutions, using a 
mix of patent and plant variety protection laws, began to protect their biotechnological 
discoveries in order to recover their enormous research investments. Biotechnological 
components and germplasm resources became concentrated in the hands of fewer and fewer 
organizations. For the most part, particularly in the area ofbiotechnological discoveries, the 
dominant organizations were in the private sector and their vision did not focus on the world's 
poor for simple pragmatic or commercial reasons. 
The CGIAR also began to study the effect ofbiotechnology on its system. The first endeavor 
was in 1989 when the World Bank convened a meeting in Canberra, Australia. But it was only in 
the mid-1990s when the CGIAR set-up two panels, one focusing on how the Centers could fulfill 
their intemational mandate from the scientific and technical perspective; the other focusing on 
implications ofthe increasingly proprietary nature ofbiotechnology. In its report, the latter panel 
recommended that the CGIAR develop expertise to manage technology transfer and IP issues, 
that current technologies used by the Centers be reviewed, and that the Centers' existing guiding 
principies on IP be reviewed, revised, formalized, and enforced. The principal recommendation, 
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the two panel reports concluded, was to ensure that the benefits of CGIAR research would 
continue to be delivered efficiently to their clients. 
Over 10 years ago, CIAT launched its own biotechnology unit (although it had practiced tissue 
culture, isozyme screening, anther culture, and embryo rescue for quite sorne time). CIAT 
biotechnology researchers, working with externa! entities, have obtained materials and related 
information from outside sources. A great part of this assistance, granted to CIA T under 
restrictive conditions through material transfer agreements {MT A), was proprietary to the donor 
in the form of technical property {TP) rights. 
In addition to the claims of TP rights in the donated materials and related information, much of 
such transferred material and related information carne to CIAT with the donor's IP claims, 
typically in the form of patents or patent applications, already in place. Receipt of such protected 
materials and related infonnation induced CIAT to institute certain restrictions on 
confidentiality, review its publication procedures, modify its processes for the release ofCIAT-
held gennplasm, and seek a clearer path forward regarding CIAT's use of and the progeny of 
donated materials and related information for later release to CIA T clients. In order to chart a 
path forward, CIA T Management commissioned a comprehensive review of IP management 
issues. This IP management review was projected to consist ofthree parts: 
l. obtaining an IP Audit; 
2. developing a strategy for regularizing CIAT's use ofnon-CIAT technology; and 
3. establishing long-term IP management guidelines. 
Developing a sound IP management policy and strategy is not an easy matter, whatever the type 
of organization involved. In essence, however, IP management is nothing more than a matter of 
risk management. No one ever definitively knows who has rights todo what with all IP. This ís 
partly the statutory protection area is in continua! flux because with new patents continually 
being issued, older patents expiring, and patent-related court settlements taking place around the 
world. Also, due to the increasing complexity of the underlying sciences, courts and judges/juries 
have increasing difficulty in making consistent decisions. This is not unusual in newly emerging 
technologies and partly the reason the appeal process. 
All that organizations can do is try to comply with the freedom-to-operate {FTO) opinions that 
they commission, establish protocols to defend (or proactively fight) their decisions and choices, 
and seek whatever licenses they believe that they need to reach their goals. 
For an institution such as CIAT, licensing issues are further clouded because CIAT clients are 
from many different countries. Thereby the statutory protection laws required for full FTO are as 
varied as the CIA T client list. Also, although a few client countries permit sorne form of 
patenting ofplants and plant parts/products, most do not permit this form ofiP protection. Most 
CIA T client countries ha ve sorne laws regarding plant variety protection (PVP) and most ha ve 
sorne ofthe TRIPs protocols in place. Most client countries assure sorne form ofTP rights 
protection based in contract law, but these rights are not universally enforced. Further, many 
client countries are extremely limited in their IP management knowledge or capacity. 
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This lea ves CIA T with the challenge as to whether or not to distribute improved germplasm with 
full FTO orto pass this responsibility for obtaining FTO, along with CIAT's improved 
germplasm, on to the client country with a caveat regarding these matters. 
Domestic consumption vs. export becomes another significant issue for CIA T as it reviews its 
client's needs. This is especially true for transgenic crops. Domestic consumption vs. export 
affects not only Proprietary Property (PP) management by CIA T and by the CIA T clients 
(whereby PP is defined as comprising intellectual property (IP) and technical property (TP) and 
related information; see page 4 for a detailed definition ofthese terms), but moves over into the 
areas ofbiosafety and intemational trade. 
Hence many of the decisions that willlead an organization such as CIA T to seek commercial 
Iicenses (whether they are royalty-free or not) must flow from a strategic plan aimed at 
developing and/or maintaining clear relationships with the private sector while at the same time 
offering CIAT clients-the national agricultura! research programs (NARSs)-products that they 
can freely deploy. The challenges of charting a clear path among the reefs ofPP rights, biosafety, 
farmers' rights and intemational trade matters are not insignificant. Yet, the importance of 
offering clear direction in this storm is what is being asked ofCIAT and the CGIAR system 
overall. · 
1.2 Conduct of the Audit 
CIAT is one ofthe sixteen CGIAR centers. It has been conducting research with non-CIAT 
proprietary material and related information for a long time. With the significant changes that 
ha ve taken place in the statutory protection environment during the last decade, CIA T is now 
seeking to protect its ability to freely distribute the products and services emanating from its 
research programs. 
As a first step, CIA T began documenting the IP or TP rights to the material and information that 
is being used in its laboratories or is being created by its efforts. CIA T is further trying to 
determine the IP or TP rights that are attached to material and information that has been obtained 
from externa} sources. These efforts are giving CIA T a clearer understanding of the complexities 
ofthese rights and how CIAT might strategically deal with these matters in the future. 
These objectives are to be achieved through a three-pronged approach: 
l . conducting a comprehensive IP Audit by: 
a. identifying the major IP components used or handled by CIAT, whether the IP is formal 
or informal; 
b. identifying who owns the IP and/or was responsible for its creation; 
c. identifying the so urce of the IP; 
d. identifying any restraints on the use, protection, or development of the IP that may affect 
CIAT's ability to access, use, or distribute its own IP or non-CIAT IP; 
e. assessing the importance ofthe IP to CIAT's activities; and 
f. identifying all new IP being developed at CIA T 
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2. identifying a strategy for regularizing non-CIA T IP currently used by CIA T researchers, and 
3. developing long-term IP management guidelines 
The Center commissioned the International Service for the Acquisition of Agri-biotechnology 
Applications (ISAAA) to conduct an IP Audit (Audit) to specifically address issues related to 
point "d" (above) for certain specified CIAT projects and prepare an overall discussion on items 
2 and 3 (above). 
The projects for in-depth analysis were determined by consultation between the Auditors and the 
Center's Management and the choices were based on including a cross section from several 
programs that would highlight sorne ofthe generic IP-related issues while providing CIAT 
management with a detailed feed-back on sorne of its current challenges. These projects were: 
• product clearance review ofrice Hoja blanca virus resistant transgenic rice 
• activities with Brachiaria and potentiallimits on distribution of improved germplasm 
• the FloraMap™ tool for the conservation of genetic resources 
Hence the Audit was designed to focus on selected parts ofCIAT's overall activity and to: 
• la y the groundwork for capacity building regarding IPffP management within CIA T 
• provide a pragmatic basis for CIAT's decisions regarding future policy changes 
These "selected parts" ofCIAT's overall activity were selected based on the following criteria: 
• highly complex projects were preferred to fairly simple ones; 
• activities that included the transfer oftechnology to CIAT; 
• projects with products for transfer to NARS were given preference; and finally, 
• projects with controversia! issues were also preferred as a way of ensuring that CIAT 
receives the necessary guidance to formalize its IP strategy and policy. 
More specifically, CIAT and the Auditors agreed: 
• "Audit" shall mean the activity of ISAAA to produce an analysis of the PP of the Projects (in 
the case ofthe FloraMap™, the Audit was limited to Argentina, Bolivia, Brazil, Columbia, 
and the United States of America) in order to identify and list the Components of each 
Project, CIAT's management ofthose Components, issues surrounding the Components, and 
to prepare a profile ofthe known statutory limitations affecting the Components. 
• "Findings" shall mean a written compilation of the Component based on information 
provided by CIAT, a discussion ofiSAAA's investigation, anda letter to CIAT's 
management. 
• "Component(s)" shall mean the subdivisions ofthe Proprietary Property ofthe Projects. 
• "Intellectual Property" shall mean, without limitation, intellectual property rights, including 
patent rights, plant variety protection certificates, unpublished patent applications, and any 
inventions, improvements, and/or discoveries that mayor may not be legally protectable, 
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including all know-how, trade secrets, research plans and priorities, research results and 
related reports, statistical models and computer programs and related reports, and market 
interests and product ideas. 
• "Technical Property and Information" shall mean, without limitation, computer software, 
germplasm and the biological materials and derivatives thereof, and related information. 
• "Proprietary Property'' is Intellectual Property and Technical Property and lnformation. 
The Audit essentially began in March 2000 with CIA T providing the Auditors with certain 
project documentation. This was followed by an on-site visit to CIA T by three senior Auditors in 
April and included detailed staff interviews. 
The Audit team is comprised of ti ve IP Specialists in Plant Biotechnology and Patent Law, who 
include R. David Kryder, the Director ofiSAAA's Global Intellectual Property & Technology 
Transfer Initiative, Dr. Anatole F. Krattiger (initially as ISAAA's Executive Director and lateras 
intemational consultant with bioDevelopments, LLC), Donna Bobrowicz (a patent attomey 
retained by ISAAA), Dr. Stanley P . Kowalski, a biochernist, and Dr. John Dodds ofDodds & 
Associates, a law firm specializing in IP that has been retained by ISAAA. In addition, 
significant support has been provided by two ISAAA IP Intems. 
A confidentiality agreement between CIA T and ISAAA was executed to cover all aspects of the 
Audit prior to entering into initial discussions. During the course of the Audit, ISAAA retained 
the services of several additional attomeys and consultants regarding topics of specific advice 
and opinion. It should be noted that ISAAA has confidentiality agreements in place, as a 
condition ofretention with all non-ISAAA attomeys and consultants. Confidentiality also binds 
all ISAAA employees and Intems, as a condition of their employment or Intemship. 
The Auditors are grateful for having been given free and timely access to CIAT senior 
management, researchers, documents, and related information as it was requested. 
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2. REVIEW OF AGREEMENTS ANO PROJECTS 
2.1 Product Clearance Review of Rice Hoja Blanca Virus Resistant Transgenic 
Rice 
2.1. 1 Rice Hoja Blanca Virus (RHBV) Resistant Transgenic Rice 
Rice and beans have been, and continue to be, of critica! importance to the dietary requirements 
of millions of people throughout Latín America. The extraordinary rate at which rice production 
has increased in this region o ver the past few decades is indicative of this trend: 
• rice production has doubled between 1966 and 1995 
• wetland rice yield increased from 3.3 to 4.6 tons (5.0 for irrigated rice)lhectare between 1966 
and 1995 
• hectares planted to rice have increased from 5.8 to 6.7 million 
This increased production, sustainability and availability of rice have been particularly important 
to the many resource-poor farmers, as well as urban poor, throughout the region. 
Rice breeding and varietal development have been important factors in the steady increase in 
production. Over the past 30 years, over 300 new varieties have been released in Latín America. 
With nearly 120 ofthese varieties originating from crosses made at CIAT, it is transparently 
obvious asto CIAT's crucial and continuing contribution to rice agriculture in the region. 
CIA T has been involved in the development of pest and disease resistant rice through traditional 
plant breeding strategies. However, recent advances in genetic engineering have permitted 
traditional plant breeders to join with biotechnology researchers to project possibilities for other, 
very significant means to reduce rice losses dueto environmental stresses, pests and diseases. To 
this end, researchers at CIAT have been actively developing transgenic rice with durable 
resistance to rice hoja blanca virus (RHBV). RHBV is a tenuivirus, with a divided ssRNA 
negative sense genome. It is a major viral disease agent of rice throughout the Caribbean region, 
central and northern Latín America. RRBV is transmitted by leafhoppers (Tagosodes orizicolus), 
which are also negatively impacted by the virus. RHBV is transmitted in a persistent, circulative 
manner, characteristically with sporadic severe epidemics followed by hiatuses wherein the 
RRBV levels are low. Major outbreaks have been reported to cause up to 80% yield reductions 
Breeding programs have developed rice varieties with partial resistance to RHBV. However, 
these lines provide inadequate defense since plantlets younger than 25-days-old display 
significant susceptibility to the virus. To help plug this portal of susceptibility, and augment the 
airead y existing sources of resistance, CIA T has undertaken a project to genetically engineer the 
RRBV nucleoprotein (N) gene into the rice genome. Rice transformed with this gene display 
significant reduction in disease development when challenged with RHBV, relative to 
susceptible controls. RRBV resistance ofthis transgenic rice is mediated by the viral N gene 
cloned in the sense direction. The N gene is on the virus complimentary strand ofRNA 3. The N 
protein is predicted to consist of 319 amino acids with a molecular mass of 35,336. The 
resistance mechanism in transgenic rice was thought to be a type of coat protein-mediated cross 
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protection. By eventually introgressing this gene(s) from the transformed rice into rice varieties 
which already express the endogenous resistance phenotype, i.e., bred-resistance, a "pyramiding" 
ofresistance factors may well ensure stable, durable resistance throughout the rice plant's entire 
period of growth, from planting to harvest. 
The project, funded in part by the Rockefeller Foundation's Intemational Program on Rice 
Biotechnology, is fairly well advanced. However, as CIA T researchers are proceeding with their 
product development work, CIA T management is looking at related IP and TP issues. IP rights 
issues center on statutory protection rights (patents, Plant V ariety Protection certificates, 
copyrights, etc.) while TP rights are concerned with the ownership oftangible materials used in 
research. 
Prior to CIA T transferring the improved, RHBV N gene containing rice germplasm to its clients, 
CIAT is seeking to establish its duties and obligations through a PP Audit ofthe RHBV Resistant 
Transgenic Rice Project. The Auditors ha ve conducted an extensive deconstruction of various 
components ofthe project that details information about this transgenic product's various 
components. With this information, a CIA T patent attomey will be able to produce a freedom-to-
operate opinion ("FTO") to guide CIA T management regarding risks related to releasing 
improved transgenic RHBV nucleoprotein gene transformed rice. Such a FTO opinion will 
include a review ofbiotechnology components and germplasm as well as those licenses that 
impinge on the project. 
Detailed knowledge ofCIAT's PP rights and obligations are critical for severa} reasons. First, 
CIAT will wish to maintain its reputation for ethical behavior. Second, because client (farmers, 
researchers, private companies, NARS, general public) capacity building is one ofCIAT's major 
goals, CIA T ought to consider instituting model PP rights management systems to be able to 
share its experience with NARS and other clients. Finally, because CIAT's current strategy 
includes developing collaborative research and/or commerciallicensing activities with a variety 
of non-CIA T laboratories (public and private ), CIA T will need to establish its capability to 
properly manage PP related matters for all projects, not just the RHBV Resistant Transgenic 
Rice Project. 
2.1.2 Deconstruction 
The overall scheme for a deconstruction process for the RHBV Resistant Transgenic Rice 
Project is presented below. This deconstruction process divides the germplasm and 
biotechnology aspects of a product into nine main components and fifteen sub-components: 
• plant/seed source 
• cloning vectors and process 
pBS (Stratagene System) 
cDNA synthesis 





• Selectable marker gene expression cassette 
hygromycin resistance gene (aph IV) 
CaMV 35S promoter 
Nos terminator 
• RHBV resistance gene expression cassette 
nucleoprotein (N) gene 
CaMV 35S promoter 
Nos terminator 
• transformation method 
• plant tissue culture and regeneration 
• viral coat protein mediated cross protection 




other laboratory techniques and procedures 
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Deconstruction was done by way of the Auditors posing a series of questions that seek to name 
and identify the so urce of each of the components and sub-components. Then the PP rights that 
are potentially attached to each component and sub-component were identified. This 
deconstruction activity is realized by querying the RHBV Resistant Transgenic Rice Project 
researchers, by searching various science and patent databases, and by analyzing agreements that 
CIA T has executed with non-CIA T sources. Results are entered into a RHBV Resistant 
Transgenic Rice Project Product Clearance Spreadsheet given in Table 1 (see also Appendix 1). 
This Product Clearance Spreadsheet is a confidential document that becomes the basis of a patent 
attomey's formal FfO opinion. The FfO is typically secured under attorney-client privilege. 
Further, the Product Clearance Spreadsheet and the FfO opinion ought to be regularly (at least 
annually andas the statutoryprotection landscape changes) reviewed by CIAT management. 
Finally, all ofthese documents should be classified as "CIAT CONFIDENTIAL" and ought to 
be circulated on a need-to-know basis only. 
With a regularly-updated FfO in hand and administrative systems in place that provide on-going 
PP management, CIA T will be able to produce and regular! y revise a Product Clearance Pro file 
that was produced for the RHBV Resistant Transgenic Rice Project by the Auditors (Table 2). It 
must be noted that this Product Clearance Profile is preliminary and was developed without 
benefit ofa legal FfO opinion ora complete review ofall ofCIAT's agreements with non-CIAT 
parties. 
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Table 1. Product C/earance Spreadsheet for Hoja blanca virus resistant transgenic rice 
IProtocoV Materials 
l. Plant Source 
Rice 
l. Plasmid Construct 
Note that the llst of posslble appllcable patents In thls table ls nota legal documem 
and Wlll requlre vermcatlon bv CIArs legal counsel 
ssue Dateb 
Source andlor Licensing 
atent No·• ltle nventor(s) ssi~nee ilin~ Date Requiremen!(_s) 
ultivar N ame: CICA 8, Country ofOrigin- Colombia, FAO in trust, Accession Identifier, IRRI-IRGC-53078 , Common Name - Rice, Scientific Name 
Oryza sativa• 
pVR3 [The following plasmid constructs were used in the construction ofpVR3: pRTlOl-the Kpn 1- Sst 1 fragrnent containing the 1.4 Kb R3-C8 clone was 
'nserted in this plasmid in the sense direction between the CaMV 35S promoter and Nos terminator. The fragment of clone R3-C8 was previously 
loned in pBluescript KS+ (Stratagene). pGSFR761A- the 2.3 kb hygromycin B phosphotransferase gene cassette driven by CaMV 35S promoter was 
·nserted into pBS(+) (Stratagene) and designated as pBS bygromycln. The CaMV 35S-N gene-Nos cassette was then transferred to pBS hygromycin 
o create pVR3. 
Stratagene US5128256 DNA cloning vectors with in vivo Huse et al, ~trata gene 20-Apr-89 7 Jul92 ¡Note:pBS, except its 
Corporation: pBS(+) excisable plasmids. ~ultiple cloning site is 
~as used in the almost identical to 
F<>nstruction of pBS pBluescript which is a 
~ygromycln and component of Uni-Zap 
~ubsequently with vector. The Uni-Zap XR 
pVR3 vector is covered by this 
:US patent owned by 
~tratagene which 
~pecifically prohibits any 
pffer for resale, 
~istribution or transfer to 
¡any third party. Use for 
esearch purposes only. 
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Source andlor Licensing 
IProtocol/ Materials IPatent No·• Title !Inventor(s) Assignee IFmog Date ssue Dateb Requirement(s) 
IUS5188957 Lambda packaging extract lacking ~hort and Stratagene 26-Feb-91 23-Feb-93 
~eta-galactosidase activity ~etz 
IUS5286636 DNA cloning vectors with in vivo ¡Huse et al. Stratagene 21-May-92 15-Feb-9~ 
excisable plasmids. 
¡EP0286200 DNA cloning vectors with in vivo ~orge et al. Stratagene 12-Jan-88 12-0ct-8~ 
excisable plasmids. 
rwos8oso8s DNA cloning vectors with in vivo !Huse et al. Statagene 12-Jan-88 14-Jul-8~ 
excisable plasmids. 
pRTIOl pRTI01 and PGSFR761A 
J>GSFR761A ¡were brought to CIA T by 
!Dr. Jorge Mayer from !Max Planck Institute and 
IPiant Genetics Systerns 
espectively. There is no 
Material Transfer 
Agreement or other 
docurnentation attached. 
~ Promoters CaMV 35S-2 CaMV 35S CaMV with 2x enhancer?) 
US4407956 Cloned cauliflower mosaic virus DNA Howell [The Regents of Univ. 13-Mar-81 4-0ct-8 
as a plant vehicle pf California 
US5352605 Chimeric genes for transforming plant Fraley et al. ~onsanto Co. 28-0ct-93 4-0ct-94 
ells using viral promoters 
US5858742 ~himeric genes for transforming plant Fraley et al. iMonsanto Co. 24-Jun-96 12-Jan-9S 
f:ells using viral promoters 
US5550318 !Methods and compositions for the ~darns et al. pekalb Genetics 9-Aug-90 27-Aug-9~ 
production of stably transformed, 
ertile monocot plants and cells 
thereof 
¡wo84029I3 ~himeric genes suitable for expression tFraley Monsanto Co. 16-Jan-84 2-Aug-8~ 
· n plant ce lis ~Rogers 
t.JS5322938 lONA sequence for enhancing the !McPherson & Monsanto Co. 17-Nov-9..< 21-Jun-9~ 
~fficiency of transcription ~ay 
~. cONA Synthesls (1.4kb cONA clone R3-C8 derived from the 3' region of the Co1omblan lsolate of RHBV RNA3) 
jUS5668005 poned genes encoding reverse ¡K.otewicz & Life Technologies 12-Mar-96 16-Sep-9' 
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Protocol/ Materials ~itle llnventor(s) IAssi~nee Filio~ Date ssue Dateb ISource and/or Llcenslng atent No.a IRequirement(s) 
S. Selectable marker ~ene (hnomycln pbospbotransferase B , aphiV) 
~S5668298 ~electable marker for development of fWaldron C. Eli Lilly and Co. 7-Jun-95 16-Sep-9 Almost identical to 
¡vectors and transformation systerns in Applicant) US6048730 but With 
[plants different assignee. 
~S6048730 ~electable marker for development of fWaldron C. Novartis AG 19-Sep-9(] 11-Apr-OC Almost identical to US 
tvectors and transformation systerns in 5668298 but with different 
[plants assignee. Subject to 
errnina1 disclaimer. 
IEP0186425 lA selectable marker for development Waldron C. Lilly Co. Eli (US) 18-Dec-85 2-Jul-8~ 
¡ofvectors and transformation systerns 
n plants 
6_. Transforma don method Blolistic 
US4945050 Method for transporting substances Sanford et al priginal assignee: 13-Nov-84 31-Jul-90 Biolistic apparatus (POS-
·nto living cells and tissues and ~ornell Flesearch 1000/He) was purchased from 
apparatus therefor IFoundation, licensed Bio-Rad. Biolistic technology 
o Du Pont with ·s exclusively licensed to Bio-
exclusive rights Rad from Du-Pont de Nemours & Co . License 
states that apparatus is solely 
tor research, and not for 
ommercial use or 
~pplications . For any 
FOmmerciallicensing, user 
¡must contact Du Pont. Letter 
~clmowledging license 
agreement sent to Bio-Rad, 
accepted. Refer to App. 6&7 
rus5100792 ~ethod for transporting substance into Sanford et al Original assignee: 24-Jan-89 31-Mar-9..! 
iving cells and tissues ~ornell Flesearch 
IFoundation, licensed 
o Du Pont with 
~xclusive rights 
russ204253 ~ethod and apparatus for introducing Sanford et al [Du Pont de Nemours 29-May-9(] 20-Apr-93 
¡t>iological substances into living cells 
Continued ... 
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ProtocoV Materlals Patent No·• Title nventor(s) Assl2nee IFilin2 Date ssue Dateb 
Source andlor Licenslng 
Requlrement(s) 
¡EP0331855 Apparatus for delivering substances 
'nto cells and tissue's in a non-1ethal 
~anford et al Biolistics, Inc. 30-Sep-88 13-Sep-89 
manner. 
¡EPS35005B 1 lmproved method and apparatus for Bruner et al Du Pont de Nemours 29-Apr-91 24-Aug-94 
·ntroducing biological substances into 
iving cells. 
~09118991 ¡Improved method and apparatus for ~runer et al Du Pont de Nemours, 29-Apr-91 12-Dec-91 
·ntroducing biological substances into <:ornell Ftesearch 
iving cells. Foundations and 
Duke Uníversity 
~09220809 ~ethod of creating a transformed rice ~hristou et al Agracetus INC 15-May-91 26-Nov-9.< 
plant 
US6004287 Biolistic apparatus for de1ivering Loomís et al ¡NI A 23-Sep-98 21-Dec-99 
ubstances into cells and tissues 
W00016828 Biolistic apparatus for delivering Loomís et al ¡N/ A 23-Sep-99 30-Mar-00 
substances into cells and tissues 
~. Plant Tlssue Culture and Re2eneratlon 
US4666844 Process ofregenerating cereals <:heng S.K. !S un gene 
rrechnologies <:orp 
7 Sep 84 19-May-8 
W09419930A 1 Enhanced regeneration system for Nehra et al. ¡National Ftesearch 10-Mar-94 15-Sep-94 
ereals ~ouncil of <:anada 
US5350688 Method of regeneration of rice plants MatsunoT& IKirin Brewery (JP) 16 Jun 9..: 27-Sep-94 
)'.<.. lshizaki 
.JP1256381A2 nduction and propagation of rice ~atsunoT& Kirin Brewery <:o . 31-Mar-88 12-0ct-89 
~allus !K. Ishizaki .... td 
continued . . . 
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Protocol/ Materlals atent No·• ltle ~nventor(s) ~sslenee flllnl! Date ~ssue Dateb 
Source andlor Llcensing 
Requlrement(s) 
~. Molecular Analysis 
PCR Analysís 
US5656493 ~ystem for automated performance of ~ullís et al The Perkin Elmer 18-Feb-94 12-Aug-9, PCR machíne used was 
he polymerase chain reaction ~orporation ~om MJ Research. A 
~eneric tícense might be 
fipplicabte, from Roche 
~olecular Systerns Inc, 
1145 Atlantíc Avenue, 
!AJameda CA, 94501, USA 
Phone: 5108142970. 
F-P0236069 ~pparatus and method for performing ~ohnson et al Ce tus 25-Feb-87 9-Sep-8 
automated amplíficatíon of nucleic 
acid sequences and assays using 
heatíng and cootíng steps 
F-P0776967 Heat exchanger for use in a ~ohnson et al The Perkín Elrner 25-Feb-87 4-June-9 
emperature cycling instrument Corporatíon 
~S4683202 Process for amplifying nucleíc acid [Mullís Getus 25-0ct-85 28-Jul-8 
~equences 
US4683195 Process for amp\ifying, detecting and/ Mullís et al. Cetus 7-Feb-86 28-Jul-8 
or cloning nucleic acíd sequences 
US4965188 Process for amplifying, detecting Mullís et al. Ce tus 17-Jun-8 23-0ct-90 
andlor cloníng nucleíc acid sequences 
usíng a thermostable enzyme 
EP0509612 Process for amplifying and detecting Mullís et al. Hoffman-La Roche 27-Mar-86 21-0ct-9" 
nucleíc acíd sequences 
EP0502588 Process for amplífying nucleíc acíd Mullís Hoffman-La Roche 27-Mar-86 9-Sep-9" 
sequen ces 
Taq polyrnerase EP0502589 Kit for use in amplifying and detecting Mullís et al. Hoffman-La Roche 27-Mar-86 9-Sep-9-G Taq po1ymerase was both 
nucleíc acíd sequences purchased from Promega 
US4889818 Purified thermostab1e enzyme Gelfand et al. Cetus 17-Jun-8 26-Dec-89 and produced on premises 
IEP0258017 IPurified thermostab1e enzyme and Erlich et al. !Cetus 2 1-Aug-8' 2-Mar-88 
process for amp1ifying, detecting, 
landlor cloning nucleíc acid sequences 
lusing said enzyme ontinued ... 
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nventor{s) iAsslgnee Filing Date 
~ource andlor Licenslng 
Protoc:oV Materials atent No·• itle ssue Dateb Re<~uirement(s) 
9. Viral coat protein mediated protection 
~P240331 !Virus resistant plants having a viral Loesch-Fries 1'-'ubrizol Genetics, 1-Apr-8, 7-0ct-87 
oat protein et al. nc. 
IW09612028Al IProduction of peptides in plants as Turpen et al. Biosource 6-0ct-95 25-Apr-96 
¡viral coat protein fusions Technologies, lnc. 
[US5316931 IPlant viral vectors having Donson et al. Biosource 31-Jul-9.l 31-May-94 
!heterologous subgenomic promoters Technologies, Corp. 
or systemic expression of foreign 
genes 
[US5589367 IRecombinant plant viral nucleic acid Ponson et al. Biosource 19-Jan-94 31-Dec-96 
Technologies, lnc. 
!No agreement was signed 
10. DNA Sequencing uslng an ABI Prism 377 sequencer (Perkin-Eimer, USA) 
• Abbreviation ofCountries: EC- European Comrnunity, JP- Japan, US- United State of America, WO- World Intellectual Property Organization 
b In the USA, the terrn of utility patent depends on when patent application was filed. If the patent issued from an application filed prior to June 8, 1995, the terrn is the later of (1) 17 years 
from the date of issuance ofthe patent, or (2) 20 years from the first U.S. filing date for the patent. lfthe patent issued from an application filed on or after June 8, 1995, then the terrn is 20 
years from the first U.S. filing date for the patent. For further information, see http:/www.patents.com/patents.sht 
• Plant gerrnplasm under the auspices ofF AO. Joint Agreement between IRRI and F AO stated that IRRI shall hold the designated gerrnplasm for the benefit of the intemational 
community. IRRI shall not claim legal ownership over the designated germplasm nor shall it seek any intellectual property rights over that germplasm or related information. The 
gerrnplasm and related information avaílable directly to users through F AO, for the purpose of scientific research, plant breeding or genetic resource conservation, without restriction. 
Furtherrnore, where sarnples andlor related inforrnation are transferred to the third party, IRRI shall ensure that the receiver bound to the conditions set above. However this provision shall 




Table 2: Product Clearance Profile (Relevant Components and Techno/ogies) of 
Hoja blanca virus resistant transgenic rice 
Note lbatthe llst ol PISSible IPPIIcable patents In Ibis table ls not a legal dacument 
and wlll requlre verlllcaden bV Cllrs legal counsel 
Primary Potentiai!Existing Owner of 
Component or IP and TP on General Process, Relevant Applicable Tangible 
Technology Technology or Gene Sequence Patents License(s) Property 
Rice , Oryza Not found Designated FAO in 
sativa cv Cica trust germplasm 
8 
RHBVN cONA Synthesis Reverse US5668005 Life Technologies 
Gene transcriptase 
Viral Coat EP240331 Lubrizol Genetics lnc. 
Protein W09612028A 1 Biosource Technologies 
Mediated US5316931 Biosource Technologies 
Protection US5589367 Biosource Technologies 
Cloning pBS (Stratagene) US512856 Stratagene 
Vector US5188957 Stratagene 
US5286636 S trata gene 
EP0286200 S trata gene 
W08805085 Stratagene 
pRTIOI None in place, No MT A Max Planck 
PGSFR761A None in place, No MT A PGS. 
Selectable Promoter CaMV 35S5' US4407956, The Regents ofUC 
Marker US5352605 Monsanto Co. 
US5858742 Monsanto Co. 
US5550318 Dekalb Generics 
US5322938 Monsanto Co. 
W08402913 Monsanto Co. 
Structural Gene aphlV US5668298 Eli Lilly and Co. 
US6048730 Novartis AG 
EP186425 Eli Lilly Co. (US) 
Terminator Nos3' US5352605 Monsanto Co. 
Gene of Promoter CaMV 35S 5' See cell above See cell above 
lnterest Structural Gene RHBV None found ClAT 
Nucleoprotein (N) 
Terminator Nos 3' US5352605 Monsanto Co. 
Tissue Culture Culture initiation US4666844 Sungene Technologies 
and and regeneration W09419930A 1 Nat'l. Res. Council 
Regeneration Canada 
US5350688 Kirin Brewery (JP) 
JPI256381 A2 Kirin Brewery Co. Ltd. 
continued . .. 
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Table 2 continued 
Primary Potential/Existing Owner of 
Component or IP and TP on General Process, Relevant Applicable Tangible 
Technology Technology or Gene Sequence Patents License(s) Property 
Plant Broad method- Biolistic US4945050 Comell Research 
Transfor- specific claims Foundation (CRF) , DuPont 
mation US5100792 CRF, DuPont 
US5204253 DuPont 
US5036006 CRF 
EP0331855 Biolistics, Inc. 
EP535005BI DuPont 
W09118991 DuPont 
CRF & Duke Univ. 
W09220809 Agracetus Inc. 
US6004287 NIA 
WOOOI6828 NIA 
Mechanical PDS-1 000/He (Bio- Bio-Rad 
apparatus used Rad) 
Analytical and pre- and post- PCR US5656493 Perkin Elmer Corp. 
Molecular transfonnation EP0236069 Ce tus 
Metbods 
laboratory EP0776967 Perkin Elmer Corp. 
methods used to 
develop US4683202 Ce tus 
the transgenic Ce tus 
product US4683195 Ce tus 
US4965188 Hoffman-La Roche 
EP0509612 Hoffman-La Roche 
EP0502588 
Taq Poi EP0502589 Hoffinan-La Roche 





2.1.3 Proprietary Property Management Analysis 
Plant Seed/Source 
Rice cultivar Cica 8, the Colombian commercial variety used in the transformation experiments 
is designated as in trust germplasm (Accession No. IRRI-IRGC 53078) under the IRRI-FAO 
agreement. The global mandate for rice genetic resources conservation ís held by the 
Intemational Rice Research Instítute ("IRRI,) whíle CIAT has a regional mandate for Latín 
America. The germplasm originated from and was donated by Colombia to the IRRI Gene Bank. 
Since the germplasm is F AO designated it can be used for any agricultura} research and breeding 
purposes without any restriction. However, CIA T or any recipient of the designated germplasm 
has no rights to obtain IP protection on the germplasm or related information or clairn ownershíp 
ofthe germplasm. These particular conditions have direct ímplications on the ownershíp ofthe 
materials developed through recombinant DNA technology, particularly transformation and is 
addressed in the díscussion portion of thís Audit. It should be noted that at present, it is not yet 
clearly established within the international comrnunity whether the transformation of a 
designated line affects the F AO designated status of pro gen y. 
Gene Construct(s) 
The plasrnid p VR3 (Appendix 2) used in rice transformation was made using DNA fragments 
from plasrnid constructs, pRTlOl (Appendix 3) and PGSFR761A (Appendix 4) that are 
originally from Max Planck Institute, Germany and Plant Genetic Systems, Belgiurn, 
respectively (Figure 1). Both plasmids were brought to CIAT by Dr. Jorge Mayer without MTA 
or documentation. Dr. Mayer is a former CIA T Senior Scientist who is now with the Center for 
the Application ofMolecular Biology to Intemational Agriculture ("CAMBIA") in Canberra, 
Australia. The procedure for the construction ofthe pVR3 and the flow ofTP related to thís are 
illustrated in Fig.l. It should be noted that the transfer of TP to crea te p VR3 involved only 
fragments ofplasmids pRTlOl and PGSFR761A. pRTlOl was utilized as the source ofthe 
CaMV 35S promoter and Nos terminator for the N gene whích was earlier produced by CIAT 
researchers through cDNA synthesis. On the other hand, PGSFR761A was used as the source of 
the entire expression cassette ofthe hygromycin resistance gene (aphiV) driven by CaMV 35S 
promoter and Nos terminator. The cloning vector used to amplify these fragments in E. co/i was 
pBS (+) (Appendix 5) from Stratagene, USA. The TP contained in pVR3 therefore, appear to be 
derived from four distinct sources: a) Max Planck Institute, Germany b) CIAT, Colombia e) 
Plant Genetic Systems, Belgiurn and d) Stratagene, USA. However, since the transfer ofpRTlOl 
and PGSFR761A are not covered by MTAs, the authorized extent ofuse ofthese plasmids from 
Max Planck Institute and Plant Genetic System is not established. 
p VR3 has the following components which might be covered by IP. 
• CaMV 35S promoter, a viral promoter active in plants that may be covered by US patents 
held by the Regents ofUniversity ofCalifornia, Dekalb Genetics (now owned by Monsanto) 
also in the US and Monsanto (now owned by Pharmacia) in the US and other countries. It 
should be noted that this promoter was obtained from Max Planck Institute and Plant Genetic 
System (the latter is now owned by Aventís) and was used to drive two distinct types of 
genes, N and aph!V in two separate expression cassettes. At thís point, it is not clear 
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Figure 1: Flow chart for the construction of pVR3 and associated transfer of tangible 
properties 
Rice Hoja Blanca Virus 
(Colombian bolate) 
(Ramir et al., 1993) 
cDNA 
RrC8 clone in pBiuescript 





(CaMV 35S 5'-Nos 3' cassette) 
(Y annisc¡ ........ 1985) 
pRTlOlN l me•• 
Spbl CaMV 35S 5'-RHBV 
N-Nos 3' fragment 
PGSFR761A 
(Gritz & Davies,1983) 
digest 
2.3 Kb Bglll-Sall 










BamHI-Sall linearized pBS(+) 
pBS--CaMV 35S 5'----RHBV N--Nos 3'----Nos 3'-------aphlV-----CaMV 35S 5'-2--pBS 
pVRJ 
Source: Compiled by Reynaldo Ebora while on an IP Management training internship with ISAAA. 
References: Gritz and Davies, Gene, 25 (1983) 179-188. de Miranda et al. J Gen Virol 75, 2127-2132, 1994. 




whether the promoters used to express these two genes are identical. From the plasmid maps 
ofpRT101 and PGSFR761A provided by CIAT to the Auditors the promoter used to express 
the RHBV N gene was labeled as CaMV 35S promoter while it was CaMV 35S-2 for aph/V. 
Further details on these constructs are not yet obtained at this time. It is crucial to establish 
the actual composition of the promoters used in the transformation studies, whether it is 
CaMV 35S, tandem CaMV 35S, CaMV 35S with tandem enhancer sequence or CaMV 35S 
with additional regulatory sequence from other sources, since this aspect will determine what 
other intellectual and tangible properties are involved. 
• Nos terminator which appears to be also covered by US 5352605, a patent primarily on 
CaMV 35S promoter issued to Monsanto. This regulatory sequence was also obtained from 
Max Planck Institute and Plant Genetic System and was also used as part ofthe regulatory 
sequence ofN and aph/V genes. 
• N gene- The cDNA ofRHBV N gene was synthesized using the Superscript II reverse 
transcriptase purchased from Life Technologies, Inc., USA who holds the patent for the said 
enzyme. 
• aph/V- covered by two identical US patents, assigned to Eli Lilly and Co. and Novartis, and 
another European patent under Eli Lilly (US). There presumably exists common ownership 
ofthe invention by the two assignees ofthe two US patents, since US6048730 (Novartis) 
posts notice that "This patent is subject toa terminal disclaimer." For additional reference on 
this general subject, please refer to http://www.bitlaw.com/source/mpep/706 02.html 
• pBS ( +) cloning vector - covered by three US, a European and an Intemational patents owned 
by Stratagene. Authorized use of this plasmid vector is for research purposes only. 
Conditions are stipulated in the "Notice to Purchasers" which accompanies product (see 
Appendix 5). 
Transformation 
CIAT used a Biolistic®PDS-1000/He System from Bio-Rad Laboratories Inc. for the particle 
bombardment of rice calli. CIA T researchers did not sígn the standard purchase agreement 
(Appendix 6) from the company, but Dr. William M. Roca, Head ofthe Biotechnology Research 
Unit sent a letter (Appendix 7) to Bio-Rad indicating that the equipment will be used for research 
purposes only, specifically for the genetic transformation of cassava, rice and phaseolus beans. 
The Auditors interpret this to be in lieu of, but in general compliance with the standard licensing 
agreement. In the Bio-Rad purchase agreement, the phrase "use for commercial purposes" is 
defined to include the production, use or transfer for consideration of apparatus, process, or 
product for performing the biolistic process. The use ofthe Bio-Rad PDS-1 000/He System 
brings the purchaser a research only license. This technology is exclusively licensed by DuPont 
to Bio-Rad, and for any commerciallicensing, the user must contact DuPont. The biolistic 
apparatus and transformation process for rice may fall under a cascad e of US, European and 
worldwide patents. However, the list of member states to the Patent Cooperation Treaty (PCT) 
updated on September 20, 2000 does not include Colombia, where the rice biolistic 
transformations were performed. As a consequence, the patents to the biolistic processes and 




The PCT was concluded in 1970, amended in 1979 and modified in 1984. This treaty makes it 
possible to seek patent protection for an invention simultaneously in each of a large number of 
countries by filing an "intemational" patent application which can be filed by anyone who is a 
national or resident of a contracting S tate. However, among the 8 countries that are identified as 
potential users of the technology by Dr. Lee Calvert (personal communication, 2000) only Costa 
Rica is a member ofthe PCT since August 3, 1999. Colombia, Venezuela, Ecuador, Peru, 
Panama, Haití and the Dominican Republic are not party to the treaty. This means that the three 
intemational patents (W0/9118991, W0/9220809, W0/0016828) will not apply to these 
countries, because patents are country specific. Furthermore, patent claims may be granted for 
different kinds of invention, claims may be worded to cover products per se, products-by-process 
( or method), uses, or processes ( or methods). Whereas the first three types of claims generally 
extend to the products that embed the new discoveries, "process or methods" claims or claims for 
the claimed technical methods or procedures do not necessarily extend to the products that are 
produced by the claimed processes or methods. What is of great importance for "process" claims 
is the country in which the process is applied. If the product is made in a country where those 
"process" claims have not been issued, then a license for such claimed processes is likely not 
required. 
The transformation system developed by CIA T using immature panicle might involve innovative 
steps that are not yet fully covered by any patents. It might be worthwhile for CIAT to explore 
the patentability of this technique while it is being further developed. 
Recommendation 1: CIAT may wish to explore the patentability of CIAT's 
developed transformation system using immature panicles as 
this technique is being further developed. 
This is partly also a matter of poli e y as to whether or not CIA T wishes to engage in the 
patentability of its own inventions. 
Trans(ormed Celi/Embryo Selection 
The use ofhygromycin for selection oftransformed cell appears to be covered by two US patents 
assigned to Eli Lilly and Co and Novartis AG and one European patent assigned to Eli Lilly. 
Plant Regeneration System 
The techniques CIAT used to regenerate plants may partially overlap with the claims ofUS 
patents assigned to Sungene Technologies Corp (US) and Kirin Brewery (JP), Japan patent 
assigned to Kirin Brewery Co. Ltd. and an intemational patent assigned to National Research 
Council of Canada. 
Screening /Molecular Analyses 
Screening processes used to determine transformation cover a wide range of laboratory tools, 
chemicals, processes and applications. Such screening requires the use of, but may not be limited 
to, monoclonal antibodies, probes, primers, and PCR and its requisite Taq polymerase. With the 
purchase ofmost ofthese components through normal commercial channels, from licensed 
suppliers, the purchaser is typically granted a license legitimizing use ofthat component for any 
research or commercial purpose. When, in the interest of cost savings or for any other reason, 
unlicensed supply sources provide such laboratory materials, the research project is in danger of 
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violating certain IP rights. At least sorne laboratory supplies for the CIA T RHBV Resistant 
Transgenic Rice Project, appear to have been obtained from both licensed and unlicensed 
sources. Use ofthe unlicensed materials may pose certain limitations on CIAT's eventual, 
legitimate distribution ofRHBV resistant transgenic rice products. 
Discussion with the researchers showed that Taq polymerase was either purchased directly from 
Pro mega (Madi son WI) or produced in the CIA T laboratory. CIA T researchers believe that 
production ofTaq polyrnerase for local use (within CIAT) is legal in Colombia. This assumption 
is apparently currently true because Colombia is not a member of the Patent Cooperation Treaty 
(PCT) and not listed as designated state nor covered by the intemational patent issued by the 
World Intellectual Property Organization (WIPO). 
The CIA T researchers used a PCR machine made by MJ Research In c. The PCR process is 
covered by patents owned by Hoffmann-La Roche, Inc. and F. Hoffmann-La Roche Ltd. 
(collectively called Roche). It appears that licenses are required both for the use ofthermal cycler 
and the enzyrne Taq polyrnerase. 
Viral Coat Protein Mediated Cross Protection 
The technique is covered by two US patents assigned to Biosource Technologies, Inc., a 
European patent assigned to Pioneer Hi-Breed Intemational, Inc. andan intemational patent also 
assigned to Biosource Technologies, Inc. Negotiation for license for the use ofthe technology 
may be necessary. 
2.1.4 Discussion and Conclusions 
Summary o(the deconstruction 
The deconstruction process is an in-depth analysis of a product. Timing the deconstruction 
process for any particular "soon to be released product" is a management decision. This 
management decision will depend on the length of the product development pipeline and 
resources available. Adequate time should be provided to permit product developers an 
opportunity to re-design their product development approaches, should appropriate FfO not be 
obtained. Most, if not all, ag-biotechnology companies would produce a cursory product 
deconstruction at the R&D planning stage even prior to initiating research. 
The Product Clearance Spreadsheet (Table 1 under Section 2.1.2 above) compiled the 
information obtained through the deconstruction process. It is typically a para-legal document, 
prepared by someone close to the product development process, to assist the organization's 
patent counsel. The FTO must be produced by a patent attomey. It will advise the organization 
regarding how to proceed with the product development and release process. 
The preparation ofthis spreadsheet was a tedious process since all the necessary information was 
scattered between many different departments, files, people, and documents. It should be noted 
that systematic recording of all relevant information is critica} because once certain key staff 
leaves CIAT, there is a significant loss ofinstitutional memory which would make it almost 
impossible to conduct a deconstruction of a certain product. For such a systematic recording, a 
robust laboratory notebook procedure may prove helpful. 
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Recommendation 2: CIAT should institute a laboratory notebook protocol 
To reduce the resources necessary to produce a Product Clearance Spreadsheet, FfO, and 
Product Clearance Pro file, CIA T should urgen ti y set in place protocols for universal 
laboratory notebook use and archiving. 
Note that the Auditors drafted a proposed laboratory notebook policy and working 
guidelines for CIAT's consideration; this is given in Section 2.4 below. 
Recommendation 3: Setting-up of a Database and related management practices 
conc~rning the release of germplasm 
Also, CIA T may want to consider instituting adequate database and related management 
practices to assure that the release of all germplasm, regardless of the recipient (CIA T or 
non-CIA T), is accompanied by ·an appropriate MT A. Details of all such MT As must be 
properly archived, searchable, and readily reportable. 
The Product Clearance Profile (Table 2 also under Section 2.1.2 above) is a brief(often one 
page) sumrnary ofthe Product Clearance Spreadsheet. It shows the organization which 
components have FfO (through licensing or in other ways) and which do not. 
The Product Clearance Spreadsheet, FfO, and Product Clearance Pro file ought to be regular! y 
(at least annually) reviewed and updated. All three are confidential and should be shared only on 
a need-to-know basis. Depending on the laws ofthe country(ies) involved, ifproperly managed, 
a FfO may fall under attomey-client privilege and thereby be protected from the discovery 
process, if lawsuits subsequently occur. 
A summary ofthe possible licenses required is given in Table 3 below (which is a surnmary of 
Tables 1 and 2). The table demonstrates that if CIA T were to seek licenses or clearances for all 
the components covered by patents it might need to contact at least 24 organizations. However, 
an important distinction is necessary here, namely between Patent Cooperation Treaty (PCT) 
member countries and non-members. Many ofthese patents apply only to PCT member 
countries. The patents found in the reviewed product willlikely not apply to the countries 
identified as potential users ofRHBV resistant transgenic rice technology at this time, because, 
with the exception of Costa Rica, they are not (yet) PCT members. 
Until recently, individuals and firms from the industrialized world typically did not incur the 
expenses of filing for patents in developing countries. In more recent years however, many 
developing countries have signed the World Trade Organization!Trade Related Aspects of 
Intellectual Property (WTOffRlPs) agreements which has led toa new burst on filing for patents 
in WTO member countries. All countries that are identified as poten ti al users of the RHBV 
resistant transgenic rice technology are members ofWTO, namely: 
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Table 3: Possible Required Licenses and/or Agreements for Hoja blanca virus 
resistant transgenic rice 
Sample Jable 
Tbe table belew sbould be ceaapleted bV CIATs legal couasel froaa data from Table1 
whlcb bas lleen updated/veñHed bV legal counsel 
License and/or 
Organization Possible Relevant Patents Agreement 
Agracetus Inc. W09220809, US6004287, W00016828 
Biolistics, Inc. EP0331855 
Bio-Rad PDS-1 000/He 
Biosource Technologies W09612028Al, US5316931, US5589367 
Ce tus EP0236069, US4683195, US4965188, 
EP0258017 
Cetus thereafter Hoffman-La Roche US4683202, US4889818 
Comell Research Foundation US5036006 
Comell Research Foundation, DuPont US4945050, U S 5100792 
Comell Research Foundation, DuPont W09118991 
&Duke Univ. 
Dekalb Genetics US5550318 
DuPont US5204253,EP535005Bl 
Eh Lilly and Co. US5668298, EP186425 
Hoffman-La Roche EP0509612,EP0502588,EP0502589 
Kirin Brewery (JP) US5350688,JP1256381 
Life Technologies US5668005 
Max Planck Institute, Germany pRTlOl, No 
MTA 
Monsanto Co. US5352605, US5858742, US5322938 
W08402913, US5352605, US5352605 
National Research Council of Canada W09419930A 1 
Novartis AG US6048730 
Perkin Elmer Corp. US5656493,EP0776967 
Lubrizol Genetics Inc. EP240331 
Plant Genetic System, Belgium PGSFR761A, 
NoMTA 
Regents ofUniv. ofCalifomia US4407956 
Stratagene US512856, US5188957, US5286636 
EP0286200, W08805085 
Sungene Technologies US4666844 
Note that although a company may own another company (e.g. DuPont having purchased Pioneer Hi-Bred 
International lnc.), certain patents may still be owned and/or rights assigned to Pioneer in which case certain 
licenses may have to be sought from Pioneer. Deterrnining the current ownership is a relatively tedious process and 




• Costa Rica - 1 January 1995 
• Peru - 1 January 1995 
• Venezuela - 1 J anuary 199 5 
• Dominican Republic - 9 March 1995 
• Colombia - 30 April 1995 
• Ecuador - 21 J anuary 1996 
• Haití - 30 January 1996 
• Panama - 6 September 1997 
TRIPs agreements require the signatories to established and maintain a prescribed level of IP 
rights protection. Thus, with the rise of a more global economy, technologically advanced 
products such as RHBV resistant transgenic rice may be produced, distributed and consumed on 
a worldwide basis. Therefore, the effects of IP and TP rights must be considered on a more 
global scale than was previously necessary. Furthennore, CIAT, although operating in Colombia 
where no relevant patents ha ve been issued, is not free of the TP rights issues that are involved 
(see also the next sub-section on the distinction between IP and TP rights). 
Recommendation 4: Product Clearance Spreadsheet and FTO Information 
CIAT should establish intemal capacity to prepare the required documentation for FTO 
Reviews. 
Specifi.c to the RHBV Resistant Transgenic Rice Project, CIA T management will need to 
consider the risks and rewards ofthe following strategic options: 
A. do not obtaín any further agreements for the components specified in the Product Clearance 
Spreadsheet 
B. obtain commerciallicenses/agreements for each ofthe components 
C. obtain commerciallicenses/agreements for selected components only 
D. reconstruct the entire RHBV resistant transgenic rice product using components for which no 
commercial license/agreement is required 
Recommendation 5: Agreement management procedures 
CIA T ought to consider a process for adequate recording, archiving and managing of its 
agreements with non-CIAT entities. This will require on-going consultation between a 
designated CIAT agreement negotiator and CIAT management. Further, it will require the 
establishment and maintenance of a database that will delineate CIAT's rights and 
obligations vis-a-vis non-CIA T entities under its agreements. 
The Critica/ Distinction between IP and TP (see also Krvder, Kowalski and Krattiger, 2000) 
Since the transfer ofTP is so closely associated with the transfer of IP it is important to define 
and identify the distinctions between the two. Scientists have traditionally exchanged materials 
among themselves for research purposes and this system has served the scientific community 
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well. Such exchanges are often formalized through MT As that stipulate the conditions by which 
materials are provided to a third party (including matters on confidentiality, under what 
conditions, if any, the material maybe transferred to another party, what happens if an invention 
takes place based on work with the material, etc.). What is often ignored is that such transferred 
material (which is the subject of TP) may contain the IP of others and that MT As typically do not 
provide the recipient with rights to use such IP. Similarly, even ifthe right for using IP 
embedded in the transferred material has been granted through licenses, such licenses do not a 
priori provide authorization to distribute the TP which was originally transferred. 
Suppose Researcher A constructs a vector with the following components: 
a) a synthetic gene constructed in his/her laboratory; and files a patent application 
b) the CaMV 35S promoter ( owned by Monsanto and obtained under a MT A from Monsanto 
for research purposes only) 
e) a plasmid which is in the public domain 
Researcher A now transfers the construct to another researcher, Researcher B, under a MT A for 
research purposes only. IfResearcher B then wishes to use a product containing the construct, 
the following agreements may be necessary: 
• A license from Researcher A for use of the synthetic gene (TP) and any related patents that 
may have been granted (IP) as specified in "a" above. 
• A license from Monsanto for use ofthe 35S promoter, as specified in "b" above. 
• A license from Researcher A for use of the plasmid {TP). Note that despite the fact that the 
plasmid is in the public domain, Researcher Y obtained it under an MT A and therefore may 
require a license to use that TP. 
More generically, CIA T has six options on how to proceed; these have been discussed more 
extensively in Kryder, Kowalski and Krattiger (2000). See Table 4 for a summary ofthese 
options. 
As a consequence, resolving the IP and TP issues becomes often much more complex than 
originally envisaged, particularly ifMTAs are involved. These MTAs are often prepared without 
consideration for what happens when research leads to new discoveries or to a developed 
product. MT As are straightforward and provide an easy way to access TP and advance research. 
Y et that easy ro u te often complicates life further down the road. 
It should not be concluded that MTAs should therefore be avoided, quite on the contrary, but the 
practica} implications of MT As are often misunderstood. 
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Table 4: Alternative andlor Complementary /PITP Management Options to Obtaining 
Freedom-to-Operate for "Any CIA T Biotechnology Product" 
Title Emphasis Description 
l. Invent Science and Research alternative ways to develop "any CIA T biotechnology product", 
around research based generating new inventions 
current approach 
patents 
2. Re-design Product Re-design each construct to reduce number of applicable patents, whenever 
constructs development possible synthesize own genes to reduce reliance on TP of others 
based approach 
3. IPffP Humanitarian All FTO issues for all "any CIA T biotechnology product" related activities, 
Owners to approach commercial or otherwise, are eliminated through public (or prívate) statements 
Relinquish focused on and related activities by the certified owners/assignees of each set ofiPITP 
Claims public ríghts for making, having made, using, having used, irnporting, exporting, 
perception selling, and having sold all "any CIA T biotechnology product" plants, plant 
parts, and al! related products and processes. 
4. Ignore all Short term All FTO issues for all "any CIA T biotechnology product" related activities, 
IP and TP perspective commercial or otherwise, are ignored, and research and product development as 
well as plans for general distribution proceed. 
5. Seek Licensing All FTO issues are resolved by the process of any party (individually or through 
Licenses approach consortia) acquiring an appropríate (commercial or other) license from the 
for alliP certified owners/assignees for each set of IPITP ríghts for the "any CIA T 
and TP biotechnology product" related activities that are of interest to the licensee. This 
license may be commercial in nature (a grant to make, have made, use, ha ve 
used, irnport, export, sell, or ha ve sold al! "any CIA T biotechnology product" 
plants and plant parts and all related products and processes) ora more 
restrictive one as the licensee and licensor mutually determine to be required. 
6. Mix ofall Pragmatic, While research and development plans are made to optimize the product, re-
Options realistic · design of constructs and acquisition on TP is planned to minimize IP and TP 
(1 to 5) conflicts (OPTION 2); selected FTO issues are removed through public (or 
prívate) rescinding of ríghts by selected holders of certain IPITP ríghts 
(OPTION 3); this "moral high ground" is used to leverage additional ríghts 
holders to either rescind their clairns (OPTION 3) orto reduce their demands 
within the context of license negotiations (OPTION 5). In the end al! remaining 
unrescinded IPffP ríghts can be either licensed (OPTION 5) or ignored 
(OPTION 4). 
Source: Adapted from Kryder, Kowalski and Krattiger (2000). The Intellectual and Technical Property Components 
ofpro-Vitamin A Rice (Go/denR.iceTM): A Preliminary Freedom-To-Operate Review. ISAAA Briefs No. 20. 
ISAAA: Ithaca, NY. 56 p. 
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Recommendation 6: CIAT should clearly define its needs when negotiating and 
entering into MTAs .with non-CIAT parties 
MT As are often prepared without consideration for what happens when research leads to a 
developed product. Because MT As are straightforward and provide an easy way to access 
TP and advance research, they are often unwisely used (by many instítutions) which 
complicates things further down the product development road. It is therefore important that 
CIA T understands the ímplications of current and future MT As as relatively minor changes 
in its agreements can significantly simplify research and product distribution later on. 
Recommendation 7: Consider the establishment of an Office of General Counsel 
Lastly, CIA T may wish to consider instituting an Office of General Counsel to o versee and 
harmonize all aspects ofCIAT's legal rights and obligations among its staffmembers and 
categories of service. 
CIA T's Standard Material Transfer Agreement 
CIA T is airead y addressing the IP rights issues related to recent developments like TRIPS and 
the Convention on Biological Diversity (CBD) by establishing the CIAT's Policy on IP Rights 
(Appendix 8). The revised version of this policy was approved by the CIA T Board of Trustee in 
December 1998. The implementation ofthe said policy is defined in the following sets of 
protocols: 
• Protocol I: 
• Protocol II: 
• Protocol III: 
• Protocol IV: 
• Protocol V: 
• Protocol VI: 
For Plant Genetic Resources 
A: Plant genetic resources placed under the auspices of the F AO, 
otherwise known as the designated collection. 
B: Material obtained after the United Nations Convention on 
Biological Diversity carne into force in December 1993. 
For Breeding Lines, Elite Germplasm and Hybrid Materials 
For Materials Derived from Genetic Engineering 
For Microorganisms and Biological Control Agents 
For Publications, Databases, Software and Equipment 
For Research Products Developed by CIAT Staff 
CIA T also has a standard MT A (Appendix 9) form that covers most of the IP and TP concerns 
based on its IPR Policy. The Auditors noted the following points in the MT A that merit further 




"The material is held in trust under the terms of an agreement between CIA T and FA O, 
and the recipient has no rights to obtain Intellectual Property Rights {IPR) on the 
germplasm or related information" (emphasis added) 
Preamble 
" This MTA is written to conformfully with the provisions ofthe United Nations 
Convention on Biological Diversity, and the terms and conditions of the Agreement 
signed on 26 October 1994 between CIATand the Food and A'gricu/ture Organization of 
the United Nations (hereafter referred toas FAO),for the conservation ofthe germplasm 
col/ections kept in trust by CIAT (and named designated) under the auspices ofF A O. " 
The term "related information" needs to be defined. Examination ofthe documents (CIAT's 
Policy on IP Rights and Material Transfer Agreement) revealed that this term was used in severa! 
occasions but was not defined. Apparently, it is assumed that the term has common definition 
and interpreted in the same way by all, which, in practice, does not seem to be the case. It is 
crucial that examples of"related inforrnation" be given and its actual scope be identified because 
it will have implications as to what materials or information derived from the germplasm, 
microbial isolates or biological control agent can be patented. For instance, can a primer whose 
sequence was derived from the plant genome of a F AO designated plant be protected? Do 
genetic map or gene sequences from a F AO designated gerrnplasm fall under this protection? 
Does "related inforrnation" refers to all the biological information present in the F AO designated 
germplasm? Ifthese things are covered by "related information", then it could not be protected 
as indícated in the general provision ofthe MTA. On the other hand, under Protocol ID: For 
Materials Derived from Genetic Engineering, these biological information are classified as part 
ofthe interrnediate or final products and of derived and associated materials. This is a possible 
source of confusion later because the other contracting party who is signing the MT A will be 
relying only on the provisions indicated in that particular document. The terrn "related 
information" might be clear on the side ofCIAT because it is defined in the CIAT's IPR Policy 
and Protocols, but can be a gray area for the other party because these documents are not integral 
parts of the MT A. 
It must be clearly stated, however, that an attempt by CIAT to define the term "related 
information" in its current or near-term agreements is not recommended bere. This is a 
politically charged issue currently being addressed by the CGIAR System (e.g. 
International Centers Week 2000) and under the negotiations leading to the revisions of the 
FAO International Undertaking. CIAT must be extremely cautious in this area. 
Once the term has been defined by the intemational community, then the situation could be 
addressed by any ofthe following approaches: 
A. Include the definition of the term "related information" and identify its seo pe in the MT A. 
B. Attach the CIAT's IPR Policy and Protocols in the MTA as appendices. 




Terms and Conditions of MT A 
"Article J. This Material Transfer Agreement is between the two institutions through 
their legal representatives. " 
With respect to the RHBV Resistant Transgenic Rice Project it would be advisable to negotiate 
with Max Planck Institute and Plant Genetic System regarding plasmid coilstructs pRTIOl and 
PGSFR761A which were used as sources ofthe regulatory sequences (CaMV 358 promoter and 
Nos terminator) and aphiV gene to create pVR3, which was used in the actual rice 
transformation. Because the plasmids were used without any MT A and transgenic plants are 
airead y produced, the agreement should include conditions on the use ofthe transformed plants 
instead ofthe use ofthe plasmid. The transfer oftangible properties (DNA sequences integrated 
into the plant genome) could be determined using the available molecular data. The MTA should 
be between institutions through their legal representatives and should be prepared with the help 
ofthe researchers so that the specific technical issues to be addressed could be properly 
incorporated in the document. 
"Article 3. CIAT is distributing the germplasm described hereinfor purposes such as 
conservation, research, plant breeding or training, without any restriction. " (emphasis 
added) 
The term ''without any restriction" is contradictory to Article 4 (discussed below) and is not 
accurate since the release ofthe material is covered by a MTA which specifically defines the 
conditions that should be complied with for use of the material. This could be revised to "CIA T 
is distributing the germplasm for purposes such as conservation, research, plant breeding or 
training in accordance to the terms and conditions indicated in this MTA". 
"Article 4. The Recipient shall not claim legal ownership over the material received nor 
seek intellectual property protection over that material and related information. The 
Recipient shall not transfer the original material refe"ed to in this MT A or any copy of it 
to a third party without ensuring that the party is bound by the obligations of a Recipient 
under this MT A. The obligations of the Recipient mentioned in this MTA extend to the 
substantially equivalen! reproductive or vegetative progeny o(the material." (emphasis 
added) 
It would help ifthe terms "related information" and "substantially equivalent reproductive or 
vegetative progeny ofthe material" are defined. As indicated before, the term "related 
information" could be interpreted as any biological information derived from the plants like 
DNA or RNA sequences, protein sequences, genetic maps, etc. but has not been defmed by the 
intemational community. As a consequence, once again, CIA T must tread very carefully in this 
area. 
The term and concept "substantially equivalent reproductive or vegetative progeny of the 
material" should also, in an ideal world, be clearly defined especially for those materials 
that are products of genetic engineering. But once again, this area is currently being 
debated in different intemational fora and CIAT should await the outcome before 
inclusion of definitions of its own. 
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It could be argued that transgenics are substantially equivalent to the untransformed gennplasm 
because a transgenic carries 100% of the original genetic material. In fact, the concept of 
substantial equivalence is presently being used in the regulation of genetically modified food, 
including under Codex Alimentarius (under the auspices ofFAO and the World Health 
Organization [WHO]), an approach that is strongly opposed by the anti GMO movement. Thus, 
one could argue that should the transgenic be classified as substantially equivalent to the original 
material obtained from CIA T then its original F AO designated status is retained and thus it 
cannot be patented. This is not in agreement with the CIAT's protocol for materials derived from 
genetic engineering. 
The critica! matter of specific definitions is an area that CIA T must exert caution. Sorne specific 
technical and legal terms are ''tenns ofart", and have both technical and legal meaning (e.g. 
essentially derived variety, parental material, substantial equivalence, intermediary 
biotechnology products). In our opinion, it is not in the best interests ofCIAT at this time to 
engage in a more detailed analysis and definition ofthese terms, as these discussions are 
currently underway in a number of other fora, including within the CGIAR system (genetic 
resources policy committee) and the FAO (Intemational Undertaking on a multilateral system for 
genetic resources). It is in our opinion preferable for CIAT to allow others to define these tenns 
and the implications thereof, and then decide whether that is the definition it chooses to follow. 
Artic/e 5. The Recipient may c/aim intellectual property protection on the products of 
breeding activities through plant variety protection that is consisten! with the provisions 
ofUPOV (Union Internationale pour la Protection des Obtentions Vegetales) Convention 
of 1991, and that does not preclude others from using the original materials for their own 
breeding activities. 
The above-mentioned MTA article should also categorically classify the FAO designated 
transformed germplasm in order to clearly interpret the CIAT's IP Policy as defined in their 
Protocols presented in Appendix 8. For instance, Protocol 1: For Plant Genetic Resources, 
indicated that for germplasm placed under the auspices of the F AO, otherwise known as the 
designated collection, CIA T will not protect the plant genetic resources by any form of 
intellectual property protection if it is held in trust. It further states that the recipient will not 
claim ownership over the material and related information. However, in Protocol 111: For 
Materials Derived from Genetic Engineering, it was indicated that to ensure availability to 
developing nations of advanced biological technologies and/or intermediate or final products, 
and of derived and associated materials, CIA T may apply for intellectual property protection of 
the technologies or materials or may provide them to a collaborator on a restricted basis. Such 
arrangements will be made only when they best serve CIAT's partners. The "intermediate 
biotechnology products" is defined to include DNA probes, vector strains, gene constructs, 
primers, etc. while "final biotechnology products" include such products as transgenic 
organisms, genetic maps, etc. This contradiction seems to emanate from the dilemma of how to 
consider the transformed plant, either as "progeny'' oras the original germplasm but with 
additional genetic character. Ifthe transgenic plant will be considered as a progeny then it is like 
a product of a breeding process, and thus it can be classified as a non-designated germplasm and 
can be covered by plant variety protection. The provisions ofProtocols 1 and m, therefore, are in 
harmony. On the other hand, if it will be considered as essentially the same germplasm ( contains 
100% of the genetic characteristics of the original material) but with only additional well defined 
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genetic character, then it should be F AO designated and cannot be protected, and thus there are 
certain contradictions in Protocols 1 and m. 
Based on the opinion ofDr. Daniel Debouck (personal communication, 2000) ofCIAT, 
"Transgenesis is another way to introduce a gene from an alíen species into the desired 
crop material. The vehicle to introduce the transgene is different as compared to 
conventional breeding, and could use celVprotoplast/particle bombardment, 
Agrobacterium, etc. From a FAO designation perspective, 1 don't see the difference with 
an improved line produced by conventional breeding. In doing so, the Center with 
possible associates Iosses sorne rights, because the improved line is accessible to aii and 
cannot be protected by IPR. Designation might be a strategy to maintain improved 
materials in the public domain, although 1 see the enforceability as a weak area for the 
time being and as a critica! matter for this kind of materials. Thus, given trends in IPR, 
distribution of improved materials might be better handled through MT As specially 
written for such materials." 
This opinion appears to be consistent with the CIAT protocols which basically considers the 
transformed plants as equivalent to a product of cross breeding and thus should not be F AO 
designated and eligible for plant variety protection. 
However, classifying the transgenics as similar to the progenies produced through conventional 
breeding and therefore to be protected under UPOV, might encourage the issuance of exclusive 
rights to transgenic accessions which are nearly identical to their F AO designated sources. 
Genetic transformation might therefore be used by sorne groups to circumvent F AO designation 
and stipulation that it should be made available to all for conservation, agricultura! research and 
breeding purposes. 
As part of the CIA T IP Policy on the research products developed by CIA T Staff, it was clearly 
indicated in Protocol VI that any idea, invention, process or other form of actual or potential IP 
(whether able to be protected by property rights or not) that a staffmember invents during his or 
her employment at CIAT must be disclosed, and shall belong, to CIAT. However, there is no 
clear poli e y on the research undertaken by CIA T staff in other institutions. For instance, how to 
handle the product of research conducted by CIA T staff while undertaking graduate studies 
abroad? Concerning the germplasm brought and used by CIAT's staffto foreign institutions for 
their own research, should MT As be enough or should such exchanges also be covered by 
additional research agreements? 
It appears that the policy regarding the status oftransformed germplasm and the materials 
developed through collaborative research need further clarification. It is recommended that CIA T 
should recognize this and implement a policy that comprehensively addresses these issues. 
Recommendation 8: Review and revise CIAT's standard.MTA 
CIAT should review CIAT's standard MTA for inconsistencies within the MTA and 





Brac;:hiaria grasses are the most widely grown and among the most economically important 
forages grown throughout tropical America. CIA T has targeted three major agroecological zones 
.for development of Brachiaria: savannas, forest margins and hillsides. The mission ofCIAT's 
Tropical Forages Program (TFP) is to contribute to the welfare of small farmers by increasing 
livestock production, while preserving and building the natural resource base. In Brazil alone the 
hectares of Brachiaria pastureland are estimated to be between 30 and 70 million, which is 
significant when one considers that the introduction of Brachiaria was initiated only 25 years ago. 
Recognizing this rapid deployment, utilization and increasing importance of Brachiaria, CIA T 
has established a breeding program, within the TFP, directed towards the development of 
advanced cultivars with improved characteristics, for example aluminum tolerance, insect 
(spittlebug) resistance and edaphic adaptation. The overall goal ofthis breeding program is to 
overcome sorne ofthe limitations found in the currently grown Brachiaria cultivars, which are 
widely recognized as having serious defects, e.g., susceptibility to spittlebug and failure of sward 
regeneration because of poor seed viability. 
Whereas CIAT holds one ofthe world's largest collections of Brachiaria germplasm, until 
recently exploitation of the genetic potential of this resource was limited to the evaluation and 
utilization oftargeted accessions. This was largely because the tetraploid species B. decumbens 
and B. brizantha are both apomicts that reproduce principally vía facultative apospory. Apomixis 
is a "double-edged" sword in the improvement of Brachiaria. Although it presents a 
considerable obstacle for sexual crossing and genetic recombination, if crosses can be made, and 
breeding progresses, favorable genotypes can be "fixed" vi a the apomictic mode of reproduction 
and thereafter propagated indefinitely through seed. The TFP at CIAT has been able to precisely 
manipulate this situation to institute a successful breeding program for the development of 
advanced cultivars of Brachiaria. B. decumbens and B. brizantha are cross compatible with the 
induced tetraploid B. ruziziensis. The mode of inheritance for apomixis is likely monogenic, with 
apospory (simplex, Aaaa) dominant to sexuality (nulliplex, aaaa). 
The TFP has therefore mobilized its scientific expertise and the germplasm resources in CIAT's 
collection for the purposes ofbreeding Brachiaria. As is discussed in this section ofthe Audit, 
these advances, albeit of scientific and agronomic significance, pose new and challenging 
questions regarding IP. The situation has changed in this regard; previously the distribution of 
Brachiaria was vía accessions, and the IP landscape was mostly confined to questions 
surrounding F AO-designation status. However, with the prospect of advanced cultivar 
development, the IP situation has become more complex. 
This section ofthe Audit addresses potential IP issues relating to this effort. Topics covered 
include: 
• Germplasm which has been used in the breeding program. 
• V arieties developed in the breeding program. 
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• Issues relating to F AO designation. 
• Issues relating to the CBD. 
• Registration of germplasm at CIAT's Genetic Resources Unit ("GRU''). 
• Coordination of efforts and activities between different units and programs at CIAT. 
2.2.2 Germplasm which has been used in the breeding program 
A total of eleven accessions of Brachiaria spp. went into the breeding program. Table 5 
summarizes the passport data for these specific CIA T accessions. These data were provided to 
the Auditors by Dr. John Miles. An e-mail communication of June 29, 2000 expands on sorne of 
this information, as well as comments on the somewhat meandering route which B. ruziziensis 
(CIATFOR-26871) took on itsjourney from Belgium to the CIAT collection: 
"CIAT 00606 is the commercial B. decumbens cv. Basilisk. Two ofthe accessions (B. 
brizantha CIAT 6297 and CIAT 6780) are the Brazilian commercial cv. Marandu. The 
others, all B. brizantha, are "routine" germplasm accessions. The other germplasm 
involved in the sexual breeding population is the tetraploidized, sexual B. ruziziensis. We 
received this germpl.asm "informally" from Dr. Cacilda do Valle (EMBRAPA/CNPGC). I 
do not kno:.v the detailed history of this B. ruziziensis tetraploid germplasm between 
when its creation in Belgium (at the Catholic University ofLovain) was documented 
(Swenne, A., B.-P. Louant, and M. Dujardin. 1981. lnduction par la colchicine de formes 
autotétraploides.ghez Brachiaria ruziziensis Germain et Evrard (Graminées). Agron. 
Trop. 36: 134-141.) and when we received it in about April1988. Cacilda received it 
while she was a Ph.D. student at U. ofillinois, I believe from Stanley Shank, who was a 
forage grass breeder at Gainesville, FL. Shank may have received it directly from Michel 
Dujardin, who spent severa! years in Tifton, GA, or it may have taken a more circuitous 
route from Belgium to Florida." 
After reading the Partial Draft ofthe Audit, John Miles sent the following e-mail (October 10, 
2000), to further elaborate on, clarify and amend bis previous observations on the ro u te of the 
tetraploidized B. ruziziensis: 
"I have just seen a "Partial Draft Report" (dated 090CTOO) ofthe ISAAA "CIAT 
Proprietary Property Audit". In Section 2.2.2 yo u quote me on the ro u te that the 
tetraploidized B. ruziziensis took between Belgium and CIA T. Since I wrote that ( on 
29JUNOO), I have been informed, directly by Cacilda (in an e-mail of25 August) in 
response to a direct inquiry from me, that she received this material as seed directly from 
Michel Dujardin. This was atan ASA (American Society of Agronomy) meeting 
sometime in the mid-1980's, while she was a PhD student at U. oflllinois. She grew 
plants from this seed at U. oflllinois and harvested (open-pollinated) seed from these. 
What Cacilda brought here to CIAT, in 1988, from Brazil, was vegetative material from 
plants grown in Brazil from her Illinois-harvested seed and also remnant seed from 
Illinois. I am almost certain that Stanley Shank had this material also, but apparently he 
was not the so urce of the seed sample that Cacilda received. So the path was not quite so 
"circuitous" as 1 thought in June. As far as I am aware, there is no "paper trail" to 
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Table 5: Brachiaria Passport lnformation (accession Details) 
liD ICIATFOR-16829 ICIATFOR-16827 lelA TFOR-16296 
(l:LCA-11043; BRA-
IAiternate Accession ID IBRA-004227 IBRA-004219 k>03263 
IGenus IJJrachiaria inrachiaria liirachiaria 
~pecies brizantha lbrizantha lbrizantha 
~ountry Source IZimbabwe liimbabwe !Ethiooia 
IDonor Country INot Applicable INot Applicable INot Applicable 
IFAO in trust !Y es !Y es IYes 
IJ>ate of Collection 12/27/1985 12/27/1985 11/20/1984 
~enter Receipt Date 9130/1985 9/30/1985 12131/1984 
liD ICIATFOR-16152 ICIATFOR-16126 ICIATFOR-16107 
ILCA-13469; BRA- ILCA-13373; BRA- !ILCA-13344; BRA-
IAtternate Accession ID 003026 002852 002691 
IGenus Brachiaria Brachiaria IBrachiaria 
~pecies brizantha brizantha lbrizantha 
iCountry Source Ethiopia IEthiooia !Etbiooia 
IDonor Country INot Applicable INot Applicable INot Aoplicable 
IF AO in trust !Y es !Y es IN o 
iD ate of Collection 10/30/1984 10/12/1984 10/10/1984 
~enter Receipt Date 12131/1984 12131/1984 12131/1984 
liD CIATFOR-6387 CIATFOR-6780 CIA TFOR-6297 
K-75232A-E; BRA- CPAC-3132; CNPGC-
002453, FA0-06013; 0142/80, CPI-118938; 
IAiternate Accession ID FA0-06017 ILCA-16550 G-27/28 
K;enus Brachiaria Brachiaria Brachiaria 
~pecies brizantha brizantha brizantha 
ICountry Source K en ya UDknown Unknown 
loonor Country K en va Brazil Brazil 
IF AO in trust Y es No !Y es 
IDa te of Collection !No data No data !No data 
ICenter Recelpt Date ~/30/1981 10/31/1983 1/31/1980 
liD lelA TFOR-606 lelA TFOR-26871 
ICPI-001694; CPI-006798; 
IBRA-001058; ILCA-
IAiternate Accession ID 10871 
IGenus IBrachiaria IBrachiaria 
~pecies ldecumbens lnaiziensis 
ICountry Source IUganda Unknown 
IDonor Country !Australia INot Applicable 
IF AO in trust !Y es IN o 
ID ate of Collection !No data 11/26/1990 
~enter Receipt Date 1/1/1973 18131/1990 
Sources: http://oldsinger.cgiar.org and http://singer.cgiar.org 
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document the movement ofthis germplasm from Belgium to Illinois to Brazil to CIAT. 
(It might be interesting to see if this material was ever entered in the 
EMBRAP A/CENARGEN germplasm registry.) Nor, as far as I am aware, is there any 
documentation of the so urce of the original diploid B. ruziziensis used in Belgium to 
create the tetraploid. The original publication (Swenne, Louant, & Dujardin 
1981) is not specific as to it's identity or origin." 
During this phase ofthe Audit, it was noted that individual accessions have multiple cultivar 
names. For example, CIATFOR-606 is variously called "Pasto Amargo, Pasto Peludo, 
Brachiaria, Chontalpo, and Senal." In further communications with John Miles (July 1, 2000), 
Auditors learned that: 
"There is a 'tradition' in Latín A.merica for a single genetic entity to be released under 
different cultivar manes in different countries. It is a violation ofthe International Code 
of Nomenclature for Cultivated Plants ( see http :/ /www .ishs.org/sciliracpcod.htm). CIA T 
not only tolerates, but actually encourages this practice, with the argument that it offers 
recognition to the various national research programs (who do the releasing). This is why 
you will generally find a list ofseveral cultivar names for anything that is at all popular." 
2.2.3 Varieties developed In the breeding program 
There are six apomictic Brachiaria hybrids which CIA T already has, or might soon ha ve that are 
slated for distribution. Four ofthese are still in early stages of development. Two are much 
further along: 
• CIA T 36061 : The original cross [ cross number 625 : B. ruziziensis clone 44-6 x CIA T 6297 
(B. brizantha cv. Marandú)] was made in 1988. 
• CIA T 36061 has been the object of negotiations between CIA T and a Mexican Seed 
Company (Semillas Papalotla, S.A. de C.V.). This is initially intended to be a research 
contract, with the purpose of evaluation of the hybrid by the seed company in order to 
determine if it has potential as a cultivar. If it indeed has commercial potential, then another 
contract would be signed involving royalties on seed sales (Carlos Lascano, personal 
communication). 
• CIAT 36062: The original cross [cross number 818: B. ruziziensis clone 44-3 x CIAT 16829 
(an accession very similar to cv. Marandú)] was made in 1990. 
• CIA T 36062 displays exceptional antibiotic resistance to the spittlebug, and a general 
freedom from foliar problems or gross deficiency symptoms. However, it does not produce 
much viable seed, and is therefore only being slightly promoted in Colombia, by vegetative 
propagation (John Miles, personal communication). 
Selected terms ofthe Aprill4, 2000 draft agreement between Semillas Papalotla, S.A. de C.V. 
(Papalotla) and CIA T (please refer to Appendix 1 O) include: 
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Commitments by CIA T 
• CIA T grants to Papalotla the sol e right for commercialization of Brachiaria hybrid CIA T 
36061 in the USA, Mexico, Central America, and Panama, the Caribbean, and South 
America and China and Australia. The rights are granted for years (14?). 
• CIA T will supply the necessary documentation, permission and all other pertinent 
information to permit Papalotla to register and protect this hybrid. 
• CIA T will ha ve the right to distribute the Brachiaria hybrid CIA T 36061 or their derived 
lines to other research collaborators worldwide, for evaluation and research purposes only. 
Commitments by Papalotla 
• Papalotla will adhere to CIA T Protocol II on Intellectual Property Rights, which is attached. 
• Papalotla will be responsible for obtaining plant variety rights under their name in each 
country and their protection according to each country's law. 
• Papalotla will pay CIAT a royalty of2% (two) of all gross seed sales ofBrachiaria hybrid 
CIAT 36061. This will be paid annually at the end ofthe year starting in 2000. Gross sales 
should include sales made to all Companies and organizations related to Papalotla. 
2.2.4 lssues relating to FAO designation 
According to Article 3 (Status ofDesignated Germplasm) ofThe Agreement Between the 
"Centro Internacional de Agricultura Tropical" (CIA T) and the Food and Agriculture 
Organization ofthe United Nations (FAO) Placing Collections ofPlant Germplasm Under the 
Auspices ofthe FAO (Appendix 11): 
• The Centre shall hold the designated germplasm in trust for the benefit of the international 
community, in particular the developing countries in accordance with the Intemational 
Undertaking on Plant Genetic Resources and the tenns and conditions set out in this 
Agreement. 
• The Centre shall not claim legal ownership over the designated germplasm, nor shall it seek 
any intellectual property rights over the germplasm or related information. 
Table 5, that summarizes the passport data (accession details) for the specific CIAT accessions 





Daniel Debouck ofCIAT's GRU has informed the Auditors that since the GRU intends to 
declare all materials received prior to December 30, 1993 as FAO-designated, these three 
accessions, all of which were received prior to that date, should be considered as F AO 
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designated germplasm (July 21, 2000 e-mail correspondence). Further to this, in an e-mail dated 
August 21, 2000, Dr. Debouck informed the Auditors that accessions 6780 and 16107 had been 
reconfirmed as designated germplasm in August 1999, as part of the periodical confirmation of 
lists to FAO. 
During the course ofthe Audit the following question arose. If any ofthese accessions had been 
distributed prior to their respective FAO designation, and ifthey subsequently became FAO 
designated germplasm, would designation retroactive? Dr. Debouck replied to this query 
(August 22, 2000 e-mail correspondence) as follows: 
"Re. your question, my understanding is that the designation process has indeed 
retroactive effects. The second joint statement by F AO and the CGIAR states: "The 
Centres recognize that many accessions designated under the Agreements with F AO were 
distributed to plant breeders and researchers prior to designation in keeping with the 
CGIAR policy for providing "unrestricted availability" to germplasm - as noted in the 
Preamble of Agreements. In dealing with this situation, Centres will request and urge that 
no intellectual property rights be sought for designated germplasm that was distributed 
prior to its designation under the F AO-CGIAR Agreement". As you know, this statement 
was approved by the CGIAR at its Mid Term Meeting of (April or May) 1998 (thus 
negotiated between F AO and IPGRI on behalf of the CGIAR during the end of 1997 and 
early 1998), and reconfirmed at Intemational Centers Week of 1998 (in November of 
1998 if m y memory is correct). The original agreement between F AO and the CGIAR 
about the in-trust collections was signed on 26 October 1994, and reconducted since. 
CIAT GRU did a designation process (somehow in hurry) in 1995, because ofthe 
Agreement F AO-CGIAR. There was a system-wide effort to reconfirm the lists of 
designated germplasms during 1999, and CIA T GRU sent lists of designated accessions 
for the three groups of commodities in August 1999 to IPGRI (putting alllists together 
and then passing them to FAO). So, this means that enforcement ofMTAs goes back 
retroactively, and this is responsibility of a particular Center dealing with specific groups 
of germplasm." 
Since, to the best understanding of the Auditors: 
• All of the crosses in the Brachíaria breeding program ha ve Brachiaria ruziziensis 
CIATFOR-26871 as a parent. 
• It appears that this is the final accession used in the breeding program to obtain F AO 
designated status. 
The retroactive effect of designation is potentially very important for this particular accession in 
the breeding program, as well as for the breeding program in general. 
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2.2.5 /ssues relating to the United Nations Convention on Biological Diversity (CBD) 
The CBD was established during the United Nations Conference on Environment and 
Development, popularlyknown as the Earth Swnmit, in Rio de Janiero, Brazil in June 1992 and 
entered into force in December 1993. Prior to the convention, genetic resources were considered 
to be a comrnon heritage with no specific owner, and therefore, they could be utilized for 
research purposes without restrictions. The common heritage principie is a central tenet of the 
International Undertaking on Plant Genetic Resources and the F AO Commission on Plant 
Genetic Resources, both established in the 1980s and involving sorne 135 countries. On the other 
hand, the CBD established that states have sovereign rights over their genetic resources and 
adopted the principie that a portion of the benefits stemming from the productive use of genetic 
resources should flow back to the nations that act to conserve and provide access to these 
resources. (Reíd, http://www3.gencat.es:81). The CBD makes a definite distinction between 
benefits derived from the use of germplasm obtained before it carne into force in December 
1993, and material obtained after that date. The Convention is not retroactive and thus 
collections h?lders are not legally obliged to share any benefits with supplying countries from 
plant material obtained pre-CBD (see Wyse Jackson, 1997, 
http:/ /www.rbg.ca/cbcn/en/newsletters/0 1 04.html). 
From an institutional perspective, CIAT, as with most ofthe other CGIAR Centers, has struggled 
with reconciling the terms specified for germplasm acquisition as defined in the CBD, which 
carne into force in December 1993, and the F AO designation of germplasm. Protocol l-B of the 
CIA T Policy Statement on Intellectual Property Rights addresses this: 
l . Any material acquired by CIA T after the UN Convention on Biological Diversity carne into 
force will be received on the basis of terms previously agreed upon by the relevant donor 
country. 
2. However, CIA T will request the country involved to agree to designate the materials under 
the Agreement with F AO. 
Exarnination of accession details from Singer (SGRP), the CGIAR System-Wide Information 
Network for Genetic Resources, indicates that of the eleven accessions, comprised of three 
species, which have been used as parents in the CIA T Brachiaria breeding population, seven 
accessions of Brachiaria brizantha, and one accession of Brachiaria decumbens were collected 
from Zimbabwe, Ethiopia, Kenya and Uganda; two accessions of B. brizantha (CIATFOR-6780 
and CIATFOR-6297) country sources are listed as unknown (both donated by Brazil in 1983); 
one accession of Brachiaria ruziziensis is listed with country source as "unknown" and donor 
country as "not applicable". 
With the possible and critica} exception of Brachiaria ruziziensis CIATFOR-26871 , these 
accessions all appear to be F AO designated. Therefore, since they were collected prior to 
December 1993 they can be used in agricultura! research and breeding purposes without 
restriction, i.e., are not bound by the provisions ofthe CBD. This situation would be totally 
different ifthe accessions had been obtained after December 1993, especially those donated by 
Brazil and Australia but obtained in other countries. The complexity of the source/donor 
relationship (dueto the provisions ofthe CBD) would, under those circumstances, be 
compounded. Whereas one could argue that the present CIA T Brachiaria accessions, used in the 
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sexual breeding population, are not covered by the provisions laid forth in the CBD, sorne groups 
defend the position that progenies from two designated accessions are prohibited from IP 
protection. Again, this area is currently being debated and negotiated by international for a 
(CGIAR System and FAO) and CIAT should await the outcome ofthese high-level (and high 
profile) negotiations. 
2.2.6 Coordination of activities between different units and programs at CIA T 
During the course ofthe Audit, a situation ofless than satisfactory inter-unit, inter-program 
communication within CIAT was brought to the attention ofthe Auditors. The central issues 
concerned CIA T registration of germplasm vs. F AO designation of germplasm, and F AO 
designation of germplasm vs. granting of commercial rights to such germplasm. 
The specific situation regards CIAT 36061 (cited above). Whereas the GRU had intended, and 
was in the process of, registering CIAT 36061 as FAO designate, the TFP was (correctly, the 
Auditors believe) under the impression that CIAT and Semillas Papalotla, S.A. de C.V. were 
engaged in negotiations for a commercial contract which would grant Semillas exclusive rights 
to CIA T 36061. F AO designation of gennplasm and the granting of exclusive commercial rights 
on a germplasm seem to be mutually incompatible an directly contradictory. Furthermore, the 
TFP was not aware that the GRU would (apparently) routinely follow CIAT registration of 
germplasms with F AO designation, unless there was an explicit request not to proceed. 
The Audit, in this instance, was conducted in "real-time", in that it facilitated communication 
between concemed partí es, and thereby circumvented a misunderstanding which might have 
otherwise resulted in an unpredictable outcome. 
2.2.7 Discussion and Recommendations 
Germplasm Issues Relating to the CIA T Papalotla Agreement 
All germplasm that is released by CIA T is to be released under a standard MT A (Appendix 9) 
and is categorized as Designated Germplasm. 
The CIAT MTA does not address the issue of germplasm progeny as it is impacted by FAO-
designation. Indeed, there is still a significant worldwide debate on this point. When the debate is 
resolved, CIAT's policies and procedures regarding germplasm release and distribution may 
need to be reviewed in the light ofthat resolution. Such changes could significantly affect the 
terms of the CIA T -Semillas Agreement. 
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Recommendation 9: CIAT should designate a person responsible for monitoring 
developments under the CBD and FAO regarding FAO-
desJgnations 
A person should be specifically designated to ensure CIA T is well infonned regarding the 
latest developments, and possibly contribute to the debate and negotiations with its 
expertise. Subsequently¡ the person should review all relevant policies and agreements to 
ensure consistency and compliance. 
Since it appears that both parents of a CIA T 36061 are Designated Germplasm, then a recipient 
(including CIAT) may be prohibited, under terms ofthe Designated Germplasm MTA, from 
seeking ( or offering) any sort of IP rights protection. Because CIA T 36061 is, by definition, 
progeny ofits parents, it is unclear asto the obligations that a recipient (either CIAT or Semillas) 
may have regarding such hybrids if one or both parents are designated germplasm. 
There appears to be a general understanding and compliance with the obvious and readily 
understood terms ofthe CIAT-Papalotla Agreement by CIAT. However, on a more profound 
level, the CIAT- Papalotla Agreement may not be intemally consistent with CIAT's institutional 
goals. That inconsistency creates a high likelihood of misunderstanding among the parties 
regarding their respective rights and obligations. For CIAT's part, a faithful adherence to the 
CIAT- Papalotla Agreement in its current form, may, ata minimum, require significant 
modifications of sorne of CIA T' s policies and procedures. 
Recommendation 10: Review and possibly re-negotiate the agreement witb 
Semlllas Papa.otla, S~ de C.V • 
.. . , •t 
. . e , 
Beoause mutual trust is j)le IJlQSt critical factor in ~y r:elations]}ip, p~ctijarly be.tween 
parties who are newly esJablishing their relationship, it may be valuable for CIAT and 
Papalotla to review the CIA T- Papalotla Agreemetit together, and if,necessary to re-
negotiate üs tenns. 
. -
. ,-~ 
Under the CIA T MTA for Designated Germplasm (Appendix 9), the recipient of such 
germplasm agrees " .. . not to claim ownership over the germplasm to be received, nor to seek IPR 
over that germplasm or related information." Because the issue of germplasm progeny is not 
resolved, this provision may be at odds with those terms of the CIA T- Papalotla Agreement 
which grants certain sol e or exclusive rights to CIA T 36061 by Papalotla. 
Although an Audit ofthe CIAT-FAO Germplasm Agreement (Appendix 11) is beyond the scope 
ofthis IP Audit, CIAT Management is advised to review its obligations and their implementation 
under the CIAT-FAO Germplasm Agreement (Appendix 11). Specific areas for CIAT 
Management to monitor and adjust as appropriate: 
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Recommendation 11: Monitor and document the source of all germplasm used in 
breeding programs 
It will be critical to monitor and document the source of germplasm that is used ~a ·thát no· 
conflict arises between the negotiated agreements pertaining to gennplasm distribútion and 
any other agr~ents that CIA T has made. Further, CIA T needs to clarify its stand 
regm:ding the germplasm .proget;ty issues. 
Recommendation 12: Establisb clear policies on negotiation witb non-CIAT parties 
to ensure consistency and compliance 
. "P.r<?t~~ls1 n~ .t<> b,e~ ~~ plP;-Ce ,to cleár~Y1~~c~+S.J1 T)' ~eg~.tiatiop ,tefl~J\ .reg. g th~~ ~ >j, 
ayc~table lmuts fornegotiating agreem~ts th an·~utstde_p,a{ty. Follo~ (o(~or t9)~. i· 
tlie signiÍlg of8uch an agreement, CIAT mánagemerit~needs to review the newly 'Signe4 l' ~~~ 
:a~ment and 1J10djfy;its.internal policies ~d·pro,f~ures tq p1~~ them consisten~:,with . · ?;~· 
suclí' án agreement. '· ' . 
Recommendation 13: Setin place a strategic response plan in the event that 
~ ' < t •. 1 ·~' conqact violations are.~eged. ·, .:. . 
:B~~e eoritrac.· ~·Vidt~~arns can ñe alleged ~[ an; tifií~~ ciAtra~gément may IÍrliden:ny.-~-.: ~ 
-;"' ' •' • ;¡ rlk;i 1 :!-:l 
wish to,develop a'strategic response plan as part oftheir overáll IP management proposal. ' . 
Thi~~ay require se~Iqp,gthe ~vice .of, an ~tt~mey who is welrversed in IP law, , . . .~ 
empioyment law, and ~ntraGt law matters. 
Recommendation 14: 'Institute a cooJldfn~tefl policy for germplasm movement 
between GRU and ot)Jer CIAT units 
The Auditors recommend that CIAT institute a coordinated policy between the GRU and 
other units at CIAT, to facilitate designation/distribution of germplasm and progenies 
derived therefrom. Misunderstandings and possible misappropriations of gennplasm can 
thereby be circumvented in a timely manner. 
Additional Recommendations 
2. It might be prudent for CIAT to further investigate the precise germplasm status of B. 
ruziziensis, determining ifthere exists any "paper trail" associated with the journey ofthis 
accession. This is particularly important since this species accession (CIATFOR-26871): 
• was obtained after a very long and circuitous route, having originated in the laboratories 
of the Catholic University of Lovain, Belgium. There is no known documentation 
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associated with that transfer. The Singer Gennplasm Database refers to the Country 
So urce as "Unknown" and the Donor Country as ''Not Applicable." (It should be noted 
that CIA T the accession was transferred prior to the entering into force of the Convention 
on Biological Diversity and hence CIA T did not act counter to its own nor the 
CGIAR/FAO agreements or policies). 
• appears to be, according to The Singer Germplasm Database, not F AO Designated 
Germplasm. 
3. With regard to the use of multiple cultivar names used for individual accessions of 
Brachiaria, and CIAT's encouragement ofthis practice, CIAT may want to reconsider such a 
"policy", and attempt to standardize the cultivar nomenclature. This action would be 
consistent with International Code ofNomenclature for Cultivated Plants, and also be in 
harmony with the conventions outlined under the UPOV convention (UPOV Convention, 
Article 13). 
Conclusions 
This IP Audit ofthe Brachiaria breeding program (sexual crossing) represents an opportunity for 
CJAT to specifically address topics relevant to the Brachiaria program, and to generally evaluate 
managerial processes of CIA T germplasm in general. Critica! components discussed herein can 
thereby be extrapolated to other crops and programs. Among sorne of the important components 
to consider are: 
• accurate record keeping of accessions used as parental materials in any breeding program, 
and their status as to F AO designation; were they collected after the CBD went into effect in 
December 1993? 
• advanced breeding lines and cultivar commercialization: Is this consistent with CIAT's 
policy on IP? Is this consistent with CIAT's policy on FAO-designated germplasm? Is this 
consistent with the rnission of CIA T? 
• coordinated and open communication between the GRU and other units within CIAT. This 
will facilitate implementation ofthe standard CIAT-wide policy on germplasm acquisition, 
utilization and distribution. 
CIAT's consideration ofthese, as well as other, points, will undoubtedly serve to facilitate 
CIAT's rnission and mandate. 
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2.3 FloraMap™: A Tool for the Conservation of Genetic Resources 
2.3.1 Background 
Under the pressure of a rapidly growing population and expanding econornies, the earth's 
biodiversity is being eroded at an alanning rate. Arnong the threatened species are plants and 
beneficia! insects that could hold the keys to food security, a safer environment, better 
medicines, and other areas that could improve the life of future generations. 
Recent intemational agreements provide at least a framework for safeguarding biodiversity. In 
order to implement these, researchers need reliable tools for key tasks, such as determining 
where wild species ofinterest can be found, and once found, can be conserved. FloraMapTM, the 
product of more than 20 years of research at CIA T, is one such too l. 
FloraMap™ (www.floramap-ciat.org/floramap/requirements2.htm) was developed using 
Geographical Information System ("GIS"), a computer system capable of assembling, sorting, 
manipulating and displaying geographically referenced information i.e. data identified according 
to the locations. Using GIS it is possible to overlay maps, climatic data and plant species found in 
particular areas and establish a correlation between habitat, plant distribution and growth, among 
others. The climates at the points of collection of individual species is assumed to be 
representative ofthe environmental range ofthe organisms. Based on this assumption, 
FloraMap™ can be used to determine where wild species ofinterest can be found, their predicted 
distribution and the areas of possible adaptation when little or nothing is known of the species' 
detailed physiology. 
With its user-friendly software linked to agroclimatic and other databases, scientists can use 
FloraMap™ to create maps showing the most likely distribution ofwild species in nature. Such 
maps are extremely valuable for tasks such as planning collection expeditions and deciding 
where to locate programs for in situ conservation. Moreover it can be used as a tool to study the 
taxonomic and genetic variation of a particular species in a particular area, interrelate plant 
distribution with climatic conditions, map distribution of crop pests and their natural enernies in 
relation to the climatic condition and plan agricultura! development in a certain area. Overall, it 
is also an important tool in research leading to the formulation of national policies. 
FloraMap ™ consists of clima tic data and maps of various tropical regions of the world as data 
input, and a software to interrelate the map with climatic data and plant distributions. CIA T is 
distributing FloraMapTM, in the form ofa CD-ROM and Manual for a one-time payment of 
US$100. 
2.3.2 Development of F/oraMap TM 
The reason for having investigated the chronology ofthe development ofFloraMap™ is related 
to the possible need to further document the origin of data that was inputted into the product over 
the years, particular} y the terms under which such data was acquired. 
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Recommendation 15: CIAT should establish procedures for internally sharing 
essential research data 
It is recommended that CIAT establish a protocol to follow when intemal research data is 
shared among scientists between different divisions and/or projects. This shouJ.d ensure that 
the possible ownership can be traced as and when required. 
For practica} purposes, there are two divisions at CIA T namely The Germplasm Division and 
The Natural Resource Division. Each division handles several research projects. The projects 
under the Germplasm Division are: 
• IP-1 Improved Beans for Africa and Latín America 
• IP-2 Regional Bean Networks in Africa 
• IP-3 Improved Cassava for the Developing World 
• IP-4 Improved Rice for Latin America and the Caribbean 
• IP-5 Multipurpose Tropical Grasses and Legumes 
• SB-1 Conserving Plant Genetic Resources ofthe Neotropics 
• SB-2 Using Agrobiodiversity Through Biotechnology 
• PE-1 Integrated Pest and Disease Management 
whereas those ofthe Natural Resource Division are: 
• PE-2 Overcoming Soil Degradation 
• PE-3 Community Management ofHillside Resources 
• PE-4 Land Use in Latin America 
• PE-5 Sustainable Systems for Smallholders 
• SN-1 Rural Agroenterprise Development 
• SN-3 Participatory Research Approaches 
There are two other projects which are organized across CIAT's divisions: 
• SN-2 Partnerships for· Agricultura} Research and Development ( overseen by the Director for 
Institutional Cooperation) 
• BP-1 The Impact of Agricultura] Research (o verseen by the Director for Strategic Planning). 
FloraMap™ was developed under the Agroecological Studies Unit which for a time was named 
the Land Use/GIS Program under CIA T 's Natural Resource Division. However, in its early 
stages of development, the budget for FloraMap™ was provided under project SB-2 (Using 
Agrobiodiveristy Through Biotechnology), a part ofThe Germplasm Division. The movement of 
this project among CIAT's divisions may explain the general weakness ofrecords regarding data 
sources. This same project, later known as FloraMap™ (also as the Geographic Information 
Systems project), was more fully developed under PE-4 (Land Use in Latín America). 
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2.3.3 The Deve/opment of FloraMap TM 
This Audit will review three phases ofCIAT's GIS activities in the development ofFloraMap™: 
l . Data input: the data and databases used by CIA T to develop 
FloraMapTM 
2. Software development: 
3. The FloraMapTM product: 
CIAT's activities ofalgorithm development and 
manipulation, and 
the released CD and accompanying Manual for Use 
It should be noted that the Audit is limited in geographic scope toan analysis ofiP protection 
issues ofFloraMapTM within five countries and intemationallaw, as applicable. These countries 
of special attention for the Audit were determined in discussions between the Auditors and CIA T 
management. 




5. United States of America 
Information obtained for the Audit was based u pon communications with CIA T researchers, 
documents provided by CIAT, and documents/information which the Auditors obtained from 
various outside sources. 
Data Input 
Climatic data 
The climatic data used in the interpolations ofFloraMapTM were derived from SAMMDATA 
(South American Monthly Meteorlogical Data) which was initiated in the late 1970s and was 
maintained by Project PE-4. Later this climate database also included data from Asia and Africa, 
but the acronym was never changed. SAMMDAT A itself was extracted from 144 different 
sources and was compiled o ver the 20-year period from 1978 to 1998. Sorne of the 144 sources 
were publications but much ofthe data carne as data exchanges between CIAT researchers and 
other scientists. Details ofthe data sources ofSAMMDATA are given in Appendix 12. 
The sources of data included in the SAMMMDA T A database can be categorized as follows : 
• Primary data gathered directly by CIA T researchers 
• Secondary data, including, data gathered by the meteorology institutes of various countries 
• Tertiary data, including data obtained from scientific compilations of particular countries 
• Quatemary data, an example would be data source number 128 (see Appendix 12) which was 
obtained from the Intemational Rice Research Institute (IRRI). This data was obtained by 
CIA T from IRRl on a computer diskette containing climatic data for Malaysia which had 
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been gathered by the US Air Force 201h Weather Squadron. It is not clear what IP status this 
data has nor ifthere was an agreement in written form between IRRI and CIAT. 
The Auditors attempted to determine whether the data included in SAMMDATA were obtained 
with documented permission and were used in accordance with the restrictions, if any, that were 
specified in such documentation. Further, the question was asked as to whether such data were 
properly cited as to so urce, when included in SAMMDAT A. 
lt should be noted that in the process ofFloraMap™ development, all the climate data included 
in the FloraMap™ has been modified and is in a different form than originally received. The 
climate surfaces are completely reworked data and non e of the original data are present on the 
CD-ROM. In fact it would be very difficult to regenerate the original data from the surfaces. This 
is important since distributing the original data in a product such as FloraMap™ is more likely 
problematic whereas modified data does not present the same potential restrictions. 
With the data having been compiled by many scientísts over the period of over 20 years, the 
Auditors could not, in most cases, establish the permissions granted to CIA T for .use and 
distribution of the data nor restrictions that may ha ve been placed on the data. In this context, it 
is interesting to note an anecdotal account from one CIA T researcher that "data records (have 
literally been) written on the back on an envelope!! It really happens." ( e-mail communications, 
September 18, 2000). 
Recomm·endation 16: , CIAT should estabHsh procedures for receiVing ami sliaring 
· · 'data (ro m no o-CIA T parties 
A próposed draft for consíderation by CIA~· as prepared by.fue Auditors follo'Ys: • 
. , . ~· 
Centro Internacional 4,e !\gricultura Tropicai (CIA T) is interes~ed m receivipg you'r ot your 
organization's permission to use s,ome of y;our-or your organization's materials described 
.bet9.W;t()•beinCluded {Ó~t~~ Üílpl,"ÓVement offlotaMap™, a·software propri.'etazy ofQ~5f, 
whj:ch will be distributed for research in biodiversity conservation and other scientific 
purposes. 
Therefore, it is acknowledged by this document that you or your organization expressly 
grants CIA T permission to use those materials provided by you or your organization to be 
incorporated into the upcoming and subsequent versions ofFloraMap™, in any form now 
known or later developed, without any obligations regarding royalty or payment for· its use. 
CIAT will be pleased to acknowledge you or your organization's material(s) in a suitable 
source credit line. 
The materials supplied by you or your organization include (Piease initial a/1 applicab/e 
items): 
continued . .. 
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Y o u or your organization warrants that it owns and/or has the full authority and right to 
grant permission(s) to the material(s) offered and submitted herein. 
If you or your organization agree with the foregoing, so indicate by having an authorized 
signatory for your organization sign in the appropriate place provided below. Return this 
original copy to CIA T and retain a photocopy for your files. On behalf of CIA T, we thank 
yo u and your organization for the assistance and contribution in the development of tropical 
agriculture research. 
Prior to its execution, yo u or your organization ha ve read the abo ve and accept its conditions 
and agree to be'bound by its tenns. 
Accepted andAgreed: 
Jndividual or Organization,Name: ___..;:.:..__ ______ _ 
Authorized Signature: 




The geographic coverage included in FloraMap ™, such as locations of roads, rivers, poli ti cal 
boundaries, cities and towns, are derived from the Digital Chart ofthe World (DCW) compiled 
by United States Geological Survey (USGS; see www.usgs.gov). The DCW consists of 
cartographic attributes and textual data stored on CD-ROMs with software that permits the 
database to be accessed, queried, and displayed on personal computers. 
The DCW was developed by agencies that produce the Operational Navigation Charts (ONC) 
map series. These agencies are: 
• the United States Defense Mapping Agency 
• the Australian Army Survey Directorate 
• the Canadian Directorate of Geographic Operations, and 
• the United Kingdom Military Survey 
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These organizations were supported in the DCW design process by more than forty participating 
agencies. DCW, as produced by the USGS, is written in a special computer language which leads 
to the software ARC/INF01• 
The USGS website states that the USGS ofDCW is in the public domain. This means that the 
documents or data are not protected by copyrights and can be used by anyone. 
This version is not always correctly georeferenced2, hence it was difficult to use by CIAT. The 
Environmental Systems Research Institute (ESRI), a GIS company based at Redlands, 
California, began with the USGS version and did a considerable amount of cleaning and 
georeferencing to produce a proprietary ESRI product; the DCW-ESRI3. DCW-ESRI is 
available, on a licensed basis (Appendix 13), from ESRI in the form of 4 CD-ROMs for a fee of 
$3954• 
In the development ofFloraMap™, geographic coverages from DCW-ESRI were used after 
heavy reprocessing to cut out excessive detail. Then CIA T used, in several cases, its own 
digitized maps, such as that for Latin America. Therefore, geographic coverages in the 
shapefiles5 distributed with FloraMap™ are not the same with the originals from the DCW-
ESRI. 
Software development 
The software in FloraMapTM was written using programming control from the software 
MapObjects TM LT (Appendix 14) which is a proprietary programming software ofESRI 
(Appendix 15), distributed royalty free ata cost of$100. The CD-ROM ofMapObjects™ LT 
contains data and software. It should be noted, however, that the data from MapObjectsTM LT 
was not used in the development ofFloraMap™. 
Productlon and Dlstribution of FloraMap rM 
The first production ofFloraMap™ was done in 1998 when 20 copies of a Beta release were 
produced for review. In the further development, in January 2000, 500 copies ofversion 1 were 
produced. From the version 1 re tease, 100 copies were distributed as complimentary copies, 70 
1 ARCIINFO is Server based hybrid GIS software package, written and marketed by Environrnental Systems 
Research Institute (ESRI). Comprised of Are, the spatial GIS component and Info, a relational Database 
(www.geo.ed.ac.uk/agidexeltenn?229) 
2 To establisb tbe relationsbip between page co-ordinates on aplanar map and known real world co-ordinates 
( www .geo.ed.ac.uk/agidexeltenn? 1228). 
3 www .maproom.pru.edulfaqlques 12 .btrnl 
• htto://gisstore.esri.cornlacb/sbowdetl.cfm?&DID=6&Product ID=313&CA TID= 15 
s Sbapefiles are a digital file format for geograpbic information. The files are the standard for ESRI and are used 
primarily with ArcView desktop GIS. Tbey comprise 3 or 4 files with the same name and different extensions. 
One file has tbe actual x and y coordinates of tbe features. Anotber is a dbase file tbat bolds tbe attribute 
information for eacb map feature. Another is tbe boundary information tbat says wbat tbe geograpbic extent of 
tbe data is. 
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copies ofthe CD were lost in transit and lOO copies were sold. Eighty-two users ofFloraMap™ 
from all over the world have registered with the users group on a list server. CIA T is licensing 
the FloraMap™ for $100, and giving discounts for certain users based on application. 
The major countries, with distribution, are as follows (certain other countries include one or two 
users only): 
• USA (22) 
• Mexico (8) 
• Brazil (7) 
• UK (7) 
• Australia (6) 
• India (5) 
• Colombia (4) 
• Germany (4) 
• Belgium (3) 
• Italy (3) 
Related to the distribution ofFloraMap™ is the following: 
Recommendation 17: CIAT should study the possible implication of selling 
products (such as FloraMap'I'M or seeds) on its tax.:.exempt 
SOl (c)(3) status. 
This task should be dele~ated to an attomey well versed in tax-exempt status and accounting 
pmctices. 
2.3.4 Discusslon on Speclfic IP lssues 
Climatic data 
Climatic data for FloraMap™ carne from 144 sources of climate databases in various countries. 
However, as stated above, this Audit willlimit its review to the impact of intemationallaw and 
the laws of Argentina, Bolivia, Brazil, Colombia, and the United States on the development of 
FloraMap™. 
All ofthese counties are members ofWTO which, under TRIPS6, have to ensure a certain level 
of copyright protection as agreed under Copyright Law. Databases are protectable under 
Copyright Law. 157 countries in the world including Argentina, Bolivia, Brazil, Colombia and 
the United States are signatories ofWIPO's (World Intellectual Property Organization) 
Copyright Treaty of 19967• The Treaty extended copyright coverage to computer programs and 
databases. Noteworthy is that "this protection does not extend to the data or the material itself 





and is without prejudice to any copyright subsisting in the data or material contained in the 
compilation" (Article 5). However there are certain limitations in the protection, afforded under 
Article 1 O, which can be defined by and enacted in the respective laws of each country. 
Under WTO, TRIPS stipulates essentially that the same level of protection has to be afforded to 
data and databases. Developed country members have had to comply with all ofthe provisions of 
the TRIPS Agreement since 1 January 1996. For developing countries, the general transitional 
period was until 1 January 2000. Bolivia, Colombia, Argentina and Brazil are all considered 
developing countries under WTO. 
The Copyright Laws of Argentina, Bolivia, Brazil, and Colombia, are based on the directives of 
WIPO's Copyright Treaty and the TRIPS agreement. Copyright law in the respective countries 
differ only in the wording, but the content is essentially the same. 
For the countries under study, the copyright law as pertaining to databases and data sets can be 
summarized as follows8: 
l . Databases are protected, the protection covers the form of arrangement and expression of the 
data, insofar as the selection or arrangement ofthe contents constitute an intellectual 
creation. 
2. The protection of databases does not extend to the data or material itself. 
In the case of climatic data for FloraMap™ it is clear that: 
• Climatic data and geographic data are data, which are not covered by protection of databases 
per se. 
• All the climate data included in the FloraMap™ has been modified and presented in different 
forms than previously received when originally placed into SAMMDAT A. 
According to the two arguments presented above, it is likely that the inclusion ofthe climatic 
data used to produce FloraMap™ was not included in violation ofintemational treaty for 
copyright and the laws of Argentina, Bolivia, Colombia, Brazil and USA. However, it is not 
clear whether certain data was acquired under restricted terms which would make their further 
use in FloraMap™ subject to such restrictions. 
Geographic coverages 
The geographic coverages ofFloraMap™ were derived from the DCW ARCIINFO version from 
ESRI. The license agreement ofthe DCW-ESRI (Appendix 13) lists several terms ofrelevance 
here ( emphasis added): 
8 Argentina: 
Bolivia & Colombia: 
Brazll: 
USA: 
Presidential decree 165/94. 
Decision 351 of Cartaghena Agreement. 
Law No 961 O of February 19, 1998 on Copyright and Neighboring Rights. 
Copyright Law of the United Sta tes of America and Related Laws: 17USC§ 102. 
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• This is a license agreement, and notan agreement for sale, between the user (Licensee) and 
Environmental Systems Research Institute, Inc, a California corporation, which its principal 
place ofbusiness at 380 New York Street, Redlands, California, 92373-81000. 
• This Digital Charts of the World for use with ARCIINFO® Software License Agreement 
(Agreement) gives Licensee certain limited rights to use the Database and Related Materials. 
All rights not specifically granted in this Agreement are reserved to ESRI. 
• Permitted uses: 
o Licensee m ay install the Database or portions of the Databas e on to permanent storage 
device(s) and reproduce a corresponding number of copies ofthe Related Materials for 
Licensee's own interna! use. 
o Licensee may make only one (1) copy ofthe Original Database for archiva} purpose 
unless the right to make additional copies is granted to Licensee in writing by ESRI. 
o Licensee may modify the Database and merge other data for Licensee's own interna! use. 
The portions ofthe Database merged with other data sets will continue to be subject to 
the terms and conditions ofthis Agreement. 
o Licensee may sell, market, or otherwise distribute published hard copy renditions of the 
Database or derived portions of the Database, provided that the Licensee includes a 
legend statement acknowledging ESRI as the source ofthe portion(s) ofthe Database that 
is displayed, printed or plotted. 
• Not permitted uses: 
o Licensee shall not sell, rent, lease, sublicense, lend, assign, time-share or transfer, in 
whole or part, or provide unlicensed third parties access to the Database, Related 
Materials, any updates or Licensee's rights under this Agreement. 
o Licensee shall not reverse engineer, decompile, or disassemble in an attempt to duplicate 
the proprietary and copyright-protected ESRI ARCIINFO format. 
o Licensee shall not remarket or distribute the Database or any derived Database portion in 
digital form to unlicensed third parties. 
o Licensee shall not remove or obscure any ESRI copyright, proprietary or trademark 
no tices. 
The IP issues in the use ofDCW-ESRI in the FloraMap™ are as follows: 
l. There is no legend statement acknowledging ESRI in the FloraMap™ Manual as the source 
ofthe geographic coverages. 
2. The files distributed with FloraMap™ are not the originals from the Arc/Info version. They 
have been heavily reprocessed to cut out excess detail, although the actual points that remain 
are the same coordinates as sorne ofthe original data. The use ofFloraMap™ is not in 
conjunction with the use ofDCW ARC/INFO from ESRI, because FloraMap™ can not be 
used to draw or plot or print maps ofthe world similar to those ofthe DCW ARCIINFO. 
However, in the license terms it is specifically stated that "licensee is not permitted to 
remarket or distribute the Database or any derived Database portion in digital form to 
un/icensed third parties" ( emphasis added). Since the geographic coverages of FloraMap ™ 
can be viewed as the derivation ofthe portions from DCW-ESRI, and CIAT is distributing 
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FloraMap™ to third parties, it is advised that CIAT seeks pennission from ESRI regarding 
this matter. 
Recommendadon 18: CIAT should re-negotiate the agreement with ESRI or 
develop an altemative strategy 
The licensing agreement should be renegotiated, ~aying particular attention to these points: 
• the right to install more than one copy of the original database onto CIA T's servers 
• CIAT's failure to comply, to date, with ESRI's requirement to place certain language on 
al1 hard copy renditions of the database 
• the license requirement not to (pertaining to repditions or derivatives ofthe database) 
· '';sell, ren~ Lease, ;~,klicense, lend, ~ign_, timershare or~fer, in who1e or part, or 
, 'P.!~"(lde unh~ns~t.Ufird parti·es ~Qes8,to the l'ataba.s.e, ~elat~Materials", which CIAT 
·.:'V!olated in the pró$1Ji,ction t>fFlotaMapTM. 
lt sb_owd be noted that a renegotiation ofthe contract is not the pnlyoption; others could be 
develó~ and will depend on the relationship betwee:q ClAT and ESRI, and on the long-
tenn relationsbip ~at C~ T wishes to aevelop . 
. ~o· as~~~ disous,s~ below:.~e ,copYii~t~~lll)Íssi?9:.~~l~ease form s~~~j),y C~T 
for E.S 1s a stanaatd (qlm at ES.Rl·for the copyn~t and releáSe orm ofmatenaU,acqurred 
by BS{{!.from third parties. However, theJ etm ''us¡e" is very :btpadly defined and niay not be 
suitable for the purpose of the use ofFloraMap™ as an advertisement for MapObjects LT. 
Software development 
The software used in the FloraMap™ is written using programming control from Map Objects™ 
LT, a software from ESRI. ESRI licenses the software royalty free with certain restrictions 
contained in their License Agreement ( emphasis added): 
• License section of "Data": 
Data: NOTE that there are RESTRICTIONS ON DISTRIBUTION OF SOME OF THE 
DATA on the Maps and Data CD. Sorne ofthe data on the maps are licensed by ESRI from 
third party suppliers and may only be distributed in compliance with the distribution rights 
section ofthe on-line Data help files. 
• Copyright notification ofMapObjects LT: 
Trademark, Copyright and US Government Rights Notice: MapObjects LT is copyrighted by 
Environmental Systems Research lnstitute, Inc. All rights not specifically granted in this 
License are reserved to ESRI. 
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You (the Licensee) may use on one computer per Map Objects LT License to create maps 
and mapping functionality and distribute them without being obligated to ESRI for royalties 
or any payment beyond the Map Objects LT License fee. 
You Must Include the Following Notice in AII Documentation and in the Applications On-
line Help or Read Me File: "Portions ofthis computer programare owned by Environmental 
Systems Research Institute, lnc. Copyright © ESRI, 199 _ . AII Rights Reserved. Use, 
duplication, and disclosure by the U.S. Government are subject to restriction set forth in FAR 
§ 52.227 - 14 altemate III (g) (3) (Jun 1987) , FAR § 52.227 - 19 (JUN 1987) and/or FAR 
§12.211112.212 [Commercial Technical Data/Computer Software], and DFARS § 252.227-
7015 (NOV 1995) [Technical Data] and/or DFARS § 227.7202 [Computer Software], as 
applicable. Contractor!Manufacturer is Environmental Systems Research Institute, lnc., 380 
New York Street, Redlands, CA 92373-8100 USA. Sorne data are provided by GDT, 
Copyright Geographic Data Technology Inc. AII Rights Reserved." 
Y ou Must lnclude the Following Notice on All Media, Packaging and Documentation for 
Your Application: Mapübjects is a trademark for Environmental Systems Research Institute, 
Inc. Copyright © 199 _ Environmental Systems Research Institute, Inc. All Rights Reserved. 
There are two issues regarding software development: 
l. The Data section notification (section 1) does not apply to FloraMap™ because in the 
development ofFloraMap CIAT researchers did not use the data. Instead, they are only using 
the ESRI built programming controls. 
2. In the documentation or software ofFloraMap™ the notice above (section 2) is not included. 
Recommendation 19: 
Distribution 
Future version of the FloraMap™ Manuals should be 
revised to in~lu~e apvropriate references to ESRI software 
There are several IP issues related to the FloraMap™ as follows: 
l. Previous distribution ofFloraMap™ 
2. Use ofFloraMap™ on ESRI's website 
3. Registration ofFloraMap™ as a trademark 
4. Preventing any non-CIAT entity from copying and selling FloraMap™ 
l . Previous Distribution ofFloraMapTM 
At present FloraMap™ is distributed as a standard commercial software with a fully paid up 
license for afee ofUS$100. The Manual ofFloraMap™ cites license terms as follows: 
• ''The enclosed software is a proprietary product ofCIAT, and protected under US copyright 
law. The software may be used only by computers owned, leased, or othetwise controlled by 
you. Neither concurrent use on two or more computers nor use in a local area netwo'rk or 
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other network is pennitted without separate authorization and the payment of other license 
fees. You agree that you will not assign, sublicense, transfer, pledge, lease, rent, or share 
your rights under this License Agreement. You agree that you may not reverse assemble, 
reverse compile or otherwise translate the software. 
• Upon loading the software into your computer, you may retain the program diskettes for back 
up purposes. In addition, yo u may make one copy of the software on a second set of 
diskettes (or on cassette tape) for the purpose ofback up in the event the program diskettes 
are damaged or destroyed. You may not copy the user Manual or parts ofthe user Manual. 
Except as authorized under this paragraph, no copies of the software or the user Manual may 
be made by yo u or any person under your authority." 
According to CIAT's mandate, client countries are encouraged, particularly in the developing 
world, to use its products. Hence it is questionable whether the above license is appropriate and 
consistent with CIAT's policy. 
Reco~enda~o~ .20; · .. ~ HarinQÍllze di$t~Jib~~n of B.Iot~ap~ wi~·CIAT~s pd~cy 
or adaptCIAT's pollcies to its current practices 
¡ ' 
Both the ·ucense and licerise fee imp1y that CIAT i~ distributing FloraMap™ as a 
commercial product which may not be in accorda.qce with stated CIAT policy. 
~ . ' 
2. Use ofFloraMap™ asan advertisement on ESRI's website 
FloraMap™ is being used as ~ example of a product which can be developed using MapObjects 
LT (Appendix 14). For this purpose, CIAT signed a copyright permission and release form with 
ESRI which states (Appendix 16): 
• "Therefore, it is acknowledged by this document that you or your organization expressly 
grants ESRI and its successors and ass.igns a personal, nonexclusive, nontransferable, 
irrevocable, worldwide, royalty-free, perpetua} right, license, and privilege to use, copy, 
adapt, edit, modify, merge, reproduce, (re)print, (re)distribute, (re)broadcast, (re)transmit, 
and publicly display and/or perform the material(s) provided by you or your organization that . 
are incorporated into the upcoming and subsequent editions of ESRI Work, in any form now 
known or Iater developed, and to claim any rights, title, and interest in the overall ESRI 
Work. ESRI will be pleased to acknowledge you or your organization's material(s) in a 
suitable source credit line and proprietary rights attribution supplied by you or your 
organization." 
3. Registration ofFloraMapTM as a trademark. 
During the Audit it was found that CIAT intends to register FloraMap™ as a trademark both as 
typed drawing and as a logo in the USA. Initial searches had been performed for CIA T by 
Trademarks Etc. (Appendix 17). However, when the Auditors checked TESS (Trademark 
Electronic Search System) (Appendix 18), it was found that FloraMap is only registered as a Mark 




Recommendation 21: CIAT should fuUy trademark the word "FloraMap" together 
with the corresponding logo to prevent being blocked from 
use by a non-CIAT party 
Following discussions with CIAT, ISAAA subm*ed an application to the US Patent and 
Trademark Oflice, on behalf ofCIAT, for the wond "FloraMap" and its logo as tradeq¡arks 
(Mark Drawing Code (3): Design plus words, letters and numbers). 
This word-mark "FloraMap", however, is not owned by CIAT, but rather the owner is CIAT's 
former Director General, Dr. Grant Scobie. This should be rectified. CIA T has at least two 
options: 
l. Go back to the Trademark Oflice, and inform them that the owner is not a true representation 
of the client. The application might thereby be changed by the Trademark Office. However, 
there are several potential drawbacks to this approach. The Trademark Office might, out of 
due process, view this as a change in the application, and therefore require another fee of 
$320.00. This would also re-zero the clock for the statutory period for review (that is, back 
to 12-18 months pending registration). 
2. Retain Grant Scobie as the owner of the mark, and then execute an assignment agreement 
between Grant Scobie and CIA T. 
Recommendation 22: CIAT should ensure that the !;yp_e drawing trade~arkt-of 
"FioraMap" is in CIAT's nanie·r.ather than in thename of 
one of its former Director Gener~l 
Depending on the relationship between CIA T and its formerDirector General, execut:ing an 
assignment agreement might be the easiest option. 
4. Preventing any non-CIAT entity from copying and selling FloraMap™ 
At present CIAT distributes FloraMap™ under a commercial software license. One CD-ROM 
FloraMap™ is sold with a Manual for US$100. Ifthe demand for the product increases, a 
hypothetical software pirate could copy FloraMap™ for $0.30 per CD (plus Manual; which 
could also be put on the CD) and sell the product ata much lower cost than CIAT. At present, 
the product is copyrighted and the trademark has been sought in the USA only. 
Most countries in the world have copyright laws (see footnote 8 above), and because the main 
value ofthe FloraMap™ CD-ROM is in its software, databases and maps (and the algorithms 
and interface by which it is extracted), the content could be protected. Under most country's 
laws, this would make it illegal for any third party to copy and sell CD-ROMs containing 
protected material per se. The mechanism by which copyright is sought for each country would 
have to be determined. It should be noted that copyrighting the product would block the 
possibility that a non-CIA T entity could copyright it. 
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On the other hand, because CIA T sees its mandate to mak:e information and tools available to all 
that need it and will use it, it may be argued that there is no reason for CIA T to want to prevent 
an altemative distribution channel from being developed. 
CIA T essentially has two options to proceed with the copyright issue: 
l. Imprint the copyright symbol "©" on the CD-ROM and the Manual (as CIAT has done). 
2. Register the copyright (which is useful if and when a dispute arises) in a wide range of 
countries where FloraMapTM might have value. 
Recommendation 23: CIAT should consult with its attorney and study the pros 
and cons of registering the copyright of FloraMapTM in 
countries where the product has potential value 
Future distribution of FloraMap TM 
Recommendation 24: CJAT should consider changing the licensing terms of 
FloraMap™ 
~ 1 
While it is not against CIA T' s manda te to sell commercial products, it may be advisable for 
CIAT to distribute FloraMapTM as a "non commercial software" by modifying itswebsite 
and Manuals to include statements to the following effect: 
l. The distribution ofFloraMapTM is fornon-profit purposes only. 
2. ''Price" is charged to "coptributions toward production and distribution costs". 
3. Clearly stating tliat Fl¿raM~p i-M is distributed free from any restrictions on s~Í>sequent 
use, sale, or distribution. 
4. Clearly state the offered discount for scientific and training purposes andlor a discount 
to selected countries. · 
Whereas these options might be considered "creative", they do not, however, fundamentally 
address the issue of selling products. 
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2.4 Laboratory Notebook Policy 
2.4. 1 Background 
CIA T is entering a new era. It is considering protecting its own inventions and is engaging in 
research with other organizations, both public and private. These new relationships, often based 
on collaborative research agreements, may require precise documentation of certain activities 
and results. Laboratory and research practices will frequently need to be carefully formalized and 
noted in ways that will allow Auditors to review the authenticity of results and certify the dates 
of occurrences. Such practices are important also for potentially patenting possible discoveries 
made by CIAT ora CIAT collaborator, especially when seeking patent protection in the USA 
under the "first to invent" concepts that govem patent law in the USA. 
Recording procedures are generally spelled-out in Laboratory Notebook Procedures. These 
procedures inform all staff about the process for daily establishing and maintaining laboratory 
records that could become primary evidence for the resolution of disputes or litigation. In court, 
dates of invention, description of an invention, and research techniques can be established 
through adequately established laboratory notebooks. 
In order to achieve such goals, a bound laboratory notebook, in whatever format, must be: 
a. an honest representation of the research work done by the researcher, 
b. regularly written (daily recording is normally recommended), 
c. routinely witnessed (at least weekly) by another scientist, 
· d. duplicated when completed, ifthe researcher would like a working copy, and 
e. the originallaboratory notebook archived in a secure place or by a secure method. 
The Auditors have prepared a proposed laboratory notebook policy draft, offered below, to guide 
CIA T in the development of its own policies and procedures. These policies and procedures can 
be significantly modified to suit CIAT's needs and to harmonize with other CIAT protocols. It is 
essential, however, that any laboratory notebook policy be consistent with other laboratory 
procedures, that CIAT staffbe well trained in the executíon ofthe policy, and that the adopted 
policies be systematically enforced. 
2.4.2 Proposed Draft for Considerations 
Po/icy 
The purpose of this policy is to ensure that CIA T is sufficiently protecting its inventions, 
research, and products, so that discussions or allegations during disputes or litigation are based 
on documented fact. This includes such things as the date of an invention ora description ofthe 
invention or research, the dates or research techniques that were used can be proven without a 
doubt, and the like. In order to do this, the "laboratory notebook," in whatever format, must be an 
honest representation ofthe research work done by CIAT, and must be acceptable toa court, the 
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US Patent and Trademark Office and other offices whose charge is regulating statutory 
protection ofiP. Therefore, certain standards apply to each type ofnotebook. 
Guidelines 
l . GENERAL 
All ideas and data must be entered into a laboratory notebook. Entries must be complete enough 
that another scientist would have little or no trouble understanding and repeating the 
experiments. 
Each page must be signed by the scientist running and recording the experiment and dated each 
day, and signed and dated by a witness, ifnot immediately, then at least within one week ofthe 
scientist's signature. 
2. LABORATORY NOTEBOOK TYPES 
In deciding the exact procedures to follow, it is important to remember that any type of 
laboratory notebook must achieve two goals: 
a. show its own integrity, and 
b. corroborate the information independent ofthe person doing the research. 
Thus, the laboratory notebook must demonstrate that it has not been tampered with by 
reflecting any changes made and demonstrating that no pages have been deleted or added 
without any such change being evident and the old information being capable ofbeing 
compared with any new information. A witness, independent from your experiment, must 
attest that the information, experimentation, and/or ideas that occurred were recorded on the 
date indicated. 
A. Hardbound laboratory notebook 
Laboratory notebooks are checked out from _ name _ in the _ location _ and returned to _ 
name _ immediately upon being filled, to be microfilmed. 
When signing out a new laboratory notebook, yo u will notice that your laboratory notebook is 
numbered, is permanently bound, has index pages and that all pages are pre-numbered. 
Enter a new experiment in the index each time you start a new experiment. 
Use each page in order. Leave no blank pages between experiments. 
Record enough information so that a scientist "skilled in the art" could pick up your laboratory 
notebook and easily determine what had been done, why it had been done and what the results 
were. Entries should ínclude procedures, reagents, lot nurnbers where appropriate, sketches, 
descriptions, etc. The purpose and sígnificance of the experiment as well as observations, results 
and conclusions should be made clear. Remember, what may seem trivial or obvious at the time 
your experiments are conducted, may later be of critica! importance. 
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If you ha ve already described your experiment in an earlier experiment, or if yo u use a standard 
protocol and yo u ha ve not deviated from the previous descriptions of the experiment for your 
current one, you may reference the earlier information instead ofwriting it out again. For 
example, if yo u are starting a new experiment on page 42, and are using the same protocol as 
already described on page 25, write on page 42, "Following the protocol as described on page 25 
of this laboratory notebook ... . " 
Enter all data, in ink, directly into the laboratory notebook. 
Corrections should be made by drawing a single line through the entry. Never use erasers or 
whiteout. Initial each lineout, and if possible, put in a note of explanation next to each lineout, 
such as, "wrong data." Never tear an original page out ofyour laboratory notebook. Pages may 
be copied for your own benefit, but never removed. 
At the end of each da y puta line ora cross through any unused space on that day's page(s) in the 
laboratory notebook. If you norrnally leave a blank line between paragraphs, don 't lineout that 
one line, but if yo u ha ve a number of lines left on the bottom of the page, line them out. This wíll 
prove that you are unable to enter additional information in the laboratory notebook, in those 
empty spaces, at a later date. 
lf additional information, such as a machine generated table or graph, an original photo, autorad, 
etc., is part of your experiment and is small enough to be attached in your laboratory notebook, 
do so using glue or non-removable tape, thereby permanently attaching it in your laboratory 
notebook. Then sign your name o ver the border of the original photo, etc., crossing o ver onto the 
laboratory notebook page. Y our signature will cross o ver both the picture, etc., and the 
laboratory notebook, thereby clearly showing at any time in the future that the picture has been 
removed. 
lf your additional data is too large for your laboratory notebook, i.e., a computer printout that is a 
few pages long, such additional data can be signed, dated and countersigned and dated by your 
laboratory notebook witness and given an appropriate ID number. Y o u should al so note on such 
additional data which laboratory notebook and which page number the additional data is 
referenced. Then in your laboratory notebook you should reference the additional data's ID 
number and note the storage location where the additional data is being securely held. Preferably, 
a drawer with a set of files that are always used to store oversized information should be used. A 
sumrnary of the data can be placed in your laboratory notebook. The same sort of procedure 
should be followed with any samples that are to be kept. 
Each original page of your laboratory notebook must be signed and dated by yo u and by a 
witness. A witness should be someone who has read each entry, who is competent to understand 
what slhe has read, but who is not a co-inventor. Each research group should designate a person 
who is responsible for assigning permanent witnessing partners. However, ifyour assigned 
witness is not available when needed, you may use another person who fulfills the above criteria. 
If any changes are made after the pages are signed or witnessed, the changes must be initialed 




Use the laboratory notebook to record ideas, as these may be important in determining a date of 
invention. 
It is important to return completed laboratory notebooks to _ name _ as soon as possible to 
ensure a duplicate copy of the laboratory notebook is captured on microfilm or other permanent 
media. This process will take no longer than _ time period _. A laboratory notebook can be 
retrieved at any time during the microfilming process if needed. U pon completion of the 
microfilm process, the laboratory notebook will be returned to the researcher for use as reference 
in the laboratory or put into permanent storage per the researcher' s request. Please note that one 
microfilmed copy will be kept in the Iibrary for access at any time. One other copy ofthe 
microfilm copy will be put into secured storage at the _ storage location _. 
B. Hardbound Notebooks supplemented with data that has been electronical/y captured: 
This refers to laboratories where a large amount of data is generated and stored in the computer. 
This method still requires a written laboratory notebook with all of the guidelines referred to 
abo ve. The difference is that much of the data referenced to in the laboratory notebooks may be 
in electronic files. The laboratory notebooks should contain a summary of the information in 
those files, and also give the location ofthe computer file (the file name) under which this data is 
stored. 
Such electronic data should be backed-up and archived weekly. A new and separate file should 
be provided as a place to store data. Details ofthese files and the back-up procedure should be 
described to all researchers and managers in an attached memo. These backed-up files should 
never be opened except for litigation or Patent Office matters. 
C. Hardbound Laboratorv Notebooks generated by computers: 
The sarne guidelines apply as for the hardbound laboratory notebooks. The difference is that 
rather than purchasing a laboratory notebook and writing in it, the written material is generated 
electronically. This is printed out on a regular basis, depending on the size of the printout, and 
then bound to form a laboratory notebook. The printed material should be clearly labeled with 
the information that will appear on the front of the bound book and sent to _ na me _ for 
binding. Once bound, the laboratory notebook will be assigned a number, recorded and returned 
to the researcher or archived upon request. 
Each experiment is to be described and each page should be numbered and signed, 
countersigned, and dated. Each week these experiments are to be saved in the special data file as 
described in the attached memo. Also, as above, data such as small graphs, photos of gels, etc., 
which can be attached to the laboratory notebook page should be done so as described above, in 
a permanent manner. 
· E ven though this may be a very handy way of recording experiments, it is not the preferred way, 
for a variety of reasons. F or exarnple, if a number of experiments from different days are printed 
on one page, and the page is only signed and dated after the last entry, thereby giving rise to the 
suspicion that all the work was done as of the date of the signature. This could cause a problem 




Avoid sweeping negative statements such as ''This procedure is worthless" or ''we infringe X's 
patent with this procedure." If an experiment appeared not to give the expected result, a short 
discussion of why yo u think this happened and what could be done to follow up on the result 
should be made. Comments on infringement should never be made. 
Your laboratory notebook and its contents should be considered confidential and of great value. 
Laboratory notebooks should be stored in a secure place when they are not in use. Report the loss 
or theft of your laboratory notebook to your supervisor immediately. 
Completed laboratory notebooks that have previously been microfilmed and are no longer 
needed as reference in the laboratory should be returned to _ name _. These laboratory 
notebooks will be recorded as returned, and stored in a secured location. 
When an employee leaves CIAT, laboratory notebooks signed out and used by that person 
should be returned to the centrallocation, whether or not all pages ha ve been totally filled out. 
Depending on the number ofblank pages remaining, this laboratory notebook may be signed out 
and used by another scientist. For example, if a surnmer intem, visiting scientist, or other visitor 
has used only three pages of their own laboratory notebook, when that person lea ves, the 
laboratory notebook should be returned to _ name _, who records that s!he received it, and 
slhe can then sign it out to the next person needing a laboratory notebook, and record the new 
owner's name in hislher files. 
Keep your laboratory notebook as if each project were to be patented. Even though the work 
contained in the laboratory notebook may not result in a patent application, observance of these 
rules will provide a clear record for reports and publications. 
Audits will be conducted continuously by various designated people, both in your group and 
from other groups, to ensure that the laboratory notebook policy is being adhered to correctly. 
If yo u have problems fitting your procedures to these, please contact your patent attomey. 
Computer Back-up for Notebooks 
The 1M (Information Management or appropriate name for CIA T' s computer group) and Legal 
department should develop an archiving strategy for data in electronic form that helps satisfy 
legal concems for IP protection and complements the existing bound paper laboratory notebook 
system. 
At weekly intervals, a "snapshot" ofall the data in_ CIAT's research computers _ should be 
copied to a CD-ROM disk. The contents ofthe _ patent directory fiJes_ directory will be 
deleted after the copy is made. This CD-ROM disk will be stored in a safe vault, accessible on an 
as-needed basis by the Legal Department. Over time, then, _ CIAT _ will have time-dated 
snapshots of all this data, on a medium with a very long life. 
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3. DISCUSSION ANO CONCLUSIONS 
3.1 lntroduction 
"Keep your eye on the goal and understand the rules." This advice, from a world-class hockey 
player, arguably may apply to CIAT activities and endeavors regarding PP management (PP, 
comprising intellectual property (IP) and technical property and related information (TP)) 
beca use at no time in CIA T' s history ha ve the two-the goal and the rules of the game-been 
faster changing and been more difficult to reconcile. The very fact that CIAT works with public 
money for the public good makes it critically different from a prívate entity which works with 
prívate capital for prívate benefit. The ultimate goals ofthe two institutions-benefiting the end-
user-are essentially identical since a prívate entity can only survive ifthe end user captures a 
significant portion ofthe benefits. 
The rules of the game, however, or the way this can be achieved are intrinsically different. In that 
context, the advent ofbiotechnology in particular, and with it propríetary aspects of science, 
push CIA T enter into realms of what had previously been reserved prímarily to the prívate 
sector. Hence, business as usual is no longer feasible ifCIAT wants to take advantage of 
propríetary (not public) s~ience. 
For CIAT, its goal is clearly stated in its mission statement, "To reduce hunger and poverty in 
the tropics through collaborative research that improves agricultura! productivity and natural 
resource management." The rules of engagement, however, are rapidly changing in the 
international scene and this may make success more elusive. Increased emphasis on PP ríghts 
management, increased investments in ag-biotech by the prívate sector as well as international 
treaties such as the Convention on Biological Diversity and GATTffRIPs have altered the 
options for public organizations like CIAT. These same forces are also shifting the framework 
for CIAT's clients, the NARS and the poor fanners in developing countries. 
In order to disentangle the complexities ofiP management, it is useful to separate three types of 
activities of CIAT (let's call them the three steps). The Initial Step is access to technologies 
(information, germplasm, biotechnology, etc.). The Middle Step is work performed within 
CIA T. And the Final Step is the distribution of its technologies (be they in the form of improved 
germplasm or data or information or know-how) to its clients. 
• Initial Step: obtain, preserve, use and distribute germplasm and information and know-
how as well as those biotechnology, laboratory tools and data and 
components that are needed to produce improved CIA T mandated crops 
and to improve agricultura! management systems; 
• Middle Step: develop and produce improved germplasm (intermediary or finished) and 
agricultura! management systems through scientific and technical "value 
added" research, processes and discoveríes; and 
• Final Step: enable the release ofimproved germplasm and related information, and 
develop and share better agricultura! management systems, by national 
programs to farmers in developing countríes, prímarily poor farmers, 
whose lives are thereby improved. 
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To reach its goal more effectively, CIA T has recognized the need and value for strengthening its 
relationships with "upstream" partners, particular! y those with the private sector. CIA T has made 
significant strides in introducing such activities as collaborative research agreements and similar 
interactions. Further, CIA T has recognized value in making alliances with "downstream" 
partners in the private sector as well. 
There are severa! reasons for initiating partnerships with the private sector. Principal among 
them is that the private sector owns the majority ofthe pieces of any ofthe biotechnological 
applications; technologies that hold so much pro mise for the en tire range of CIA T clients. 
Further, as developing country seed companies begin to expand their influence, they can bring 
improved seeds to CIAT clients. While in the past, relationships between private sector entities 
and public ones, like CIA T, have been quite limited, in the future such relationships may be 
absolutely critica! for success in CIAT's future. 
Similarly, to disseminate its technologies more effectively and within the confines ofthe 
changing intemational IP regime, CIA T has adopted practices of protecting its own products and 
inventions. These practices have been implemented on an ad hoc basis and will need to be 
formalized, not least because to the outside world and private collaborators, the current strategy 
of CIA T is rather unpredictable since formal policy elements ha ve not been defined adequately 
and implementation strategies are not coherent. This makes it difficult to develop relationships of 
trust and mutual confidence in the long term. 
Relationships, whether at a personal leve! or between institutions, are built on mutual trust. 
Strong relationships are nurtured and sustained by the ability of each partner to understand and 
supply the needs of the other partner. Through the vehicle of agreements, organizations define 
how they will interact. For CIA T to be able to successfully collaborate with private sector 
organizations, it must understand what the private sector "needs," and what the private sector 
' 'wants." Then CIAT can establish the cost ínvolved (monetary or non-monetary costs), compare 
the pros and cons of different strategies, judge the relative value of different alliances, and 
determine whether or not such collaboration takes it closer to its goal. Thus. proprietary property 
rights management issues are less about "legal" documents than about building, strengthening. 
and maintaining relationships. 
As the Auditors spoke with various CIA T staff members they were impressed by the overall 
interest in and knowledge about IP related aspects and the keenness with which CIA T staff and 
management was entering into this new and uncharted area. At the same time, the Auditors 
recognized a phenomenon comrnon in any institution, namely that a range of staff members had 
reservations about new constraints imposed by PP rights management. These reservations were 
often based on a lack of understanding about how such agreements can be used to serve the 
purposes ofthe organization and thus ofprojects. At CIAT such manifestations generally fell 
into four broad areas: 
• a superficial understanding ofthe limits imposed on CIAT and non-CIAT research use of 
germplasm (Designated vs. Non-Designated). 
• the loose interpretation and understanding when distinguishing between "research" and 
"commercial" licenses as applied to various biotechnology or germplasm components. 
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• the production of unlicensed laboratory chemicals as a cost-saving measure, which is legally 
and ethically defensible ifthe chemical is not patented in the country where it is used (which 
was the case in certain examples analyzed during the Audit) but which may become a major 
stumbling block if a statutory protection is sought on subsequent discoveries. 
• the feasibility of acquiring data from and the circumstances under which certain data can 
freely be obtained, used, reproduced and distributed. 
Whereas IP management does indeed present CIAT with new constraints, it also generates new 
opportunities not previously available to an intemational research center. GoldenRice™ in this 
context is a good example to cite. As a product it is entangled in a myriad oftechnical and IP 
constraints. Still, the inventors made it clear during a speech given at the World Food Prize in 
Des Moines (October 2000) that their invention would not have been possible had it not been for 
the wealth of discoveries made, and published, by the prívate sector, and certain TP to which 
they had ready access. In a world where discoveries by the prívate sector are not always readily 
protectable, corporations might (most likely would) resort to trade secrets and thereby not 
disclose their inventions. As it is, companies are encouraged to disclose their inventions and, in 
order to optimize their revenues, license out discoveries to any institution that can add value to 
their inventions. Such out-licensing may provide the corporations with returns that are not 
necessarily monetary. 
In a perfect world, with unlimited resources, institutions may solve their problems in these areas 
by "throwing money" at the problem. An easy solution would be to hire additional personnel, 
call for stafftraining, authorize additional management positions (General Counsel, Director of 
Licensing, etc.), and add managers throughout the institution to assure that everything is done 
"according to Hoyle." 
Of course, in the real world of diminishing budgets and limited resources in which CIA T lives, 
such changes, if made, would further reduce the number of research and product development 
positions; the very critica} Middle Step in CIAT's goal-directed pathway. Therefore, a resource-
rich solution seems an impossibility for CIAT. 
Yet, CIAT is faced with the need to show that it has mastered PP rights management, iffor no 
other purpose than to inspire trust and confidence in the prívate sector. Only a "predictable" 
CIAT will gain and maintain the trust ofthe prívate sector. Further, CIAT must master PP rights 
management and do so in an economical and efficient way in order to satisfy its donors' 
perceptions and goals. 
As the Audit was conducted, projects at each ofCIAT's three goal steps were analyzed (sorne 
Audited projects bridged more than one step ). Audit observations from these projects are 
discussed below. First, we presenta synthesis ofmajor recommendations based on the projects 




3.2 The Audit: Review of a Cross-Section of Projects 
It should be emphasized at the outset that the Audit was designed to focus on selected parts of 
CIAT's activities and to lay the groundwork for capacity building regarding IP/TP management 
within CIA T. The Auditors, in cooperation with CIA T Management, agreed upon a selection of 
programs to be reviewed. The plan was to Audit the selected portions ofCIAT's activities and to 
provide a pragmatic basis for CIAT's decisions regarding future policy and strategy changes. 
The Auditors reviewed three projects in depth, prepared a Draft Laboratory Notebook Policy, 
and worked with senior management and staff on various aspects of current and ongoing 
negotiations. The Audited projects cut across CIAT's three goal-obtaining steps and therefore are 
believed to give an accurate view of PP rights management issues toda y. It should be noted that 
the Audit was not in tended to be a comprehensive overview of all of CIA T' s research and 
product development activities. 
Throughout, it has been apparent to the Auditors that CIA T, at alllevels, is doing a 
commendable job with the unnerving task of functioning under the new rules that are coming 
into play. Staff members, whether in support areas, management functions or in research were 
generally well informed and universally concemed to leam more about PP rights management. 
Throughout the organization there was a general spirit of willingness to "learn the new rules" in 
arder to continue to m ove CIA T toward its goal and in more efficient ways. 
This section will pro vide a synthesis of the specific recommendations presented which were 
distilled from the project analysis (Section 2). The recommendations are discussed in three 
groups related to the three goal-directed steps from the perspective of management 
implementation. Note that recommendations 1 O and 18 to 24 are not discussed in this section 
since they are specific recommendations related to the FloraMapTM project. 
3.2.1 lnitial Step: Access to Germplasm, Data, lnformation and Know-How 
Four critica! recommendations are related to this step, namely: 
• Recommendation 6: 
• Recommendation 8: 
CIA T should clearly define its needs when negotiating and 
entering into MT A agreements with third parties 
Review and revise CIAT's standard MTA (for accessing 
technologies and technical properties) 
• Recommendation 12: Establish clear policies on negotiation with third parties to ensure 
consistency and compliance 
• Recommendation 16: 
• Recommendation 17: 
CIA T should establish procedures for receiving and sharing data 
from third parties 
CIA T should study the possible implication of selling products 
(such as FloraMap™ or seeds) on its tax-exempt 501 (c)(3) status 
There is considerable overlap across these Audit recommendations. Certain of the 
recommendations impact one, two or all three ofCIAT's goal-directed steps. Ofparamount 
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importance to CIA T is the recognition that the accessing of nearly all germplasm, data, 
infonnation and know-how (TP rights) is done (or should be done) under a MTA. MTAs are 
based in contract law, not in IP law. Therefore, as contracts, rights under MTAs are nearly 
universally recognized and enforced; much more so than IP rights. lt is imperative that CIAT 
carefully considers what it wants to do with the TP which it obtains (middle step) from outside 
sources and how it wants to distribute such TP ( either per se or in a modified form) to its clients 
(final step). 
CIAT's goals must be clear to those conducting CIAT negotiations with outside entíties. Such 
information need not be disclosed to the outside party, but CIA T must ha ve a clear understanding 
internally ofwhat it needs and wants and what it is capable of distributing and under what terms. 
Recommendation 25: CIAT should instituti.onalize a ~entral IPffP man~gement 
offic~ to overse(aU a'p~c~ .,o~ bt:rlicens~g ·and ou,~,-licensing 
• ~ ~ ¡ 
The responsibility of such as office would, at a miniínum, include: 
' . ' 
oversee and lead all J;J.egotiation with thir.d parties; 
ensure cooi:tlination within C:fAT on all aspe~~ related to,IP and TP management; and 
- ~ume respo~ibility for the implem~ntation of procedures that refl.ect and respect the 
,. po~cies~e$bJi~hed;b~!QIAT's aoar~ ofTtustfes .and strat~gies determin.ed,by .CIAT'~ 
semor management. 
The office would also need to be. in volved and play a critica! role in the formulation of draft 
pblipies anfi)strategjes. ; ' 
3.2.2 Middle Step: ln-House Research and Development 
Seven critica! recommendations are related to this step, namely CIA T should consider: 
• Recommendation 2: instituting a laboratory notebook protocol 
• Recommendation 3: 
• Recommendation 4: 
• Recommendation 5: 
• Recommendation 11 : 
setting-up of an agreement management database and related 
management practices concerning the release of germplasm 
establishing interna! capacity to prepare the required 
documentation for Freedom-To-Operate reviews 
developing agreement management procedures 
monitoring and documenting the source of all germplasm used in 
all breeding programs 
• Recommendation 14: instituting a coordinated policy for germplasm movement between 
CIA T's GRU and other CIA T units 
• Recommendation 15: establishing procedures for intemally sharing essential research 
data across various CIA T laboratories 
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The above recommendations relate to all three management steps ofCIAT's work, reflected in 
recommendation 26 below. 
Recommendation 26: 
- ' ~ ~--~-..: ¡;_- ' 
CIA T shouldte'StalUish forUI'l ,internal procedures for the 
handling of all aspects related to IP!fP management 
These should, at a mínimum, encompass: 
internal management of data sharing and interna! technology transfer (germplasm, TP.~ 
etc.); 
intemal management of ag¡eements; and · 
procedures to ensure the protection of confi4e~tiality and the, documentation n~s~, 
for the future protection of CIA T' s own inventions. . ~. · : 
• t; :! ~· ~ . ~ 
There are different ways.tlús couldbe implementcli and'Wilhbe disoússed in more d~tail@· '·· 
Section 3.3 below. , .·. . '" ·· .· 
"" ' \ . ' ~ - ~ ·~~cqmm~Ji(l~tio.n lo/~, ·~Cl'A!.f sli(nd~ offet: .J,ffP maJia_gémént tr.aiJ,ting~~ ~~l .· 1 , •• - .• 
•; •• 1 - '! •-''t -. -}:!>~"~ 4~ '¡; • ~- .~ ·.f~·. -;t-.¡¡, 
· ~~i·~1a~~ .!o. iiP~ ~~:~~e~~i!~r~~·vlA.T,~ff ~~ m~~ge,~~~-·at y~~$!Je :~ ... ~~ 6énptcat·preJ-~lij:Site t'on~~!~n>,QotlhP).p)e.tat\~1! ofretQIDJUeA~!,tnis1~.s,;m~J~§. "<··· . -~~ir;;~ 
3.2.3 Final Step: Technology Transfer to CIA T's Clients 
The final set ofrecommendations from the analyzed projects (Section 2) relate to 
recommendation 25 regarding CIAT's need to institutionalize a central IP/TP management office 
to oversee all aspects of in-licensing and out-licensing. For example: 
• Recommendation 6: 
• Recommendation 8: 
• Recommendation 12: 
CIAT should clearly define its needs when negotiating and 
entering into MTA agreements with outside parties 
Review and revise CIAT's standard MTA 
Establish clear policies on negotiation with outside parties to 
ensure consistency and compliance 
should all be assumed by such a central office in connection with recommendation 26 above. 
The final set of recommendations is: 
• Recommendation 7: 
• Recommendation 9: 
• Recommendation 13: 
Consider the establishment of an Office of General Counsel 
CIA T should designate a person responsible for monitoring 
developments under the CBD and F AO regarding F AO-
designations 




These are related to actions which the Director General or his designate may consider to 
coordinate. 
3.3 The Audit: Policy, Management and Procedurallmplications 
There are a number of areas where hannonizing CIA T interna! policies with changing PP rights 
management realities need to be noted. These include Section 3.2 above which presented and 
discussed the specific recommendations stemming from the in-depth analysis of the three 
projects. From these, the Auditors derived severa! more generic recommendations related to 
IPffP management at CIAT. These will allow the Center to establish effective management 
procedures and should be accompanied by a review ofCIAT's IP policies and the development 
of corresponding implementation strategies. The sub-sections below discuss seven key areas in 
more detail, also addressing the possible costs involved. 
Recommendation 28: FollowingCI:AT'$ a~alysis of~he Audit, the Center should 
· coQ.duct a·comprehensive revié.w of all of i~ poli efes relatoo ·· 
to IP to ensure harOÍQnization and consistency • . 
RecogniziJJg that CIAT's IP policies have been developed partly based on the Center's 
.. needs on an op-goipg basis and partly based on e~~emal factQrs, CIA T may ~h to t:evjew 
~d hannonize all its poliqies. :this \vowd provide different levels ofmanagement with ~· ~ . 
clearer directions which are essentiai to implement effective and consistent strategies and 
management procedures. 
3.3.1 Germplasm Management 
.. 
Recommendation 129: CIAT s)Jo~ld review.its;polici~ .a~d procedu~e$ related to, 
the use ~d tJ¡ansler:,.~f germplasm, ·and to the managemt~t 
of information derivéel tbereof 
l . Record and report the receipt and distribution of all CIA T housed gennplasm; developing 
and utilizing an adequate Gennplasm Distribution Database. 
2. Assure that tenns goveming the conditions and use of all gennplasm are clearly noted to 
the recipient ( either within CIA T or outside CIA T) at time of distribution. 
3. Clarify what is required for ge~plasm to move from being Designated Gennplasm to 
~· Non-Dé'signated Germplasm. · 
~ 
4. Clarify the status of Designated Germplasm progeny. 
5. Design a means for assessing whether or not all CIA T researchers follow the prescribed 
protocols. 
Initiating hannonizing changes in the first two ofthese areas may be only a matter ofredefining 
or expanding functions that are already in place. Therefore, the cost for this may be nearly 
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negligible. But not to pro vide this is to open CIA T to using germplasm in ways that are not 
congruent with agreements that are in place. 
Points three and four are matters that is being discussed in larger intemational fora and as yet is 
not clearly determined. Until such time as clear determinations are made, CIAT is well advised 
to tread carefully in this area until more widely accepted definitions are developed and accepted 
by the CGIAR system. Both points have significant political impact. Neither can be safely 
ignored, particularly if CIA T wishes to obtain statutory protection on CIA T -made discoveries. 
The final point Design a means for assessing whether or not al/ CIAT researchers follow the 
prescribed protocols is a recurring concem the Auditors uncovered through inadequate 
documentation and discussion with various CIA T personnel. This implies widespread 
appreciation ofthe problem within CIAT anda possible statement ofwillingness to see the 
matter promptly resolved. 
It would appear that none of these points for harmonization will require the expenditure of large 
amounts of CIA T resources but, particularly the final three points, may ha ve different but large 
political ramifications and strategic implications. 
3.3.2 Central Management 
Recommendation 30i - €1Al' shóuld fornialize its vatious procedures affeéti.ílg 
IPtrP management, ranging from confidentiality to staff and 
client training 
l. A single source (for CIAT or for each major program) for all information dissem.itiation 
to the· public, sc¡entific press, interviews; etc. . . 
~ •• ' ¡. ~ .;," ~-,.,.,J~, .... ' • ., • • 
2. On-going: schedill«t,:·stMniembQr tiaürlng td ciarify CIAT's cbáhging rights and , . ! ••. 
obligations under agreements with Non-CIA T partners. · · 
• 
3. Uniformly appliedi?<>Jicy for field visitors, posters, meetings, guests, visiting.scientists, 
visitors, etc. 
4. Uniform, confidential, "declaration of invention" process. 
5. Initiation of a CIAT-wide policy on laboratory notebook usage and archiving. 
6. Access to patent databases and related search engines. 
7. Ready access to experienced negotiation services, patent counsel and general counsel 
servtces. 
8. Provision ofiPffP rights management capacity building among CIAT clients. 
Initiating harmonizing changes in the first two of these areas may be only a matter of redefining 
or expanding functions that are airead y in place, with a slight expansion of staff training. 
Therefore, the cost for this could be near negligible. 
Harmonizing of the third through fifth areas with sound PP rights management practices can be 
readily instituted at near negligible cost except for interna! and extemal political overtones. 
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CIAT management has proactively begun instituting many such changes and clearly recognizes 
the value that harmonizing such policies and procedures will bring. CIA T management seems 
likewise to understand that not instituting these changes has potential to bring CIA T into conflict 
with its clients as well as its non-CIAT collaborating partners and may effectively prevent CIAT 
from protecting discoveries made by its researchers. 
The next two points (patent databases and professional services) are critically important to PP 
rights management. These services tend to be quite expensive, so if these are instituted, CIA T 
will ha ve to closely monitor their use for excessive resource drain. While the simplest approach 
to obtaining such services would be to add additional trained personnel, this is also the most 
resource expensive solution. 
Asan altemative to CIAT employing more staffmembers and instituting these functions for 
itself, it may be resource enhancing to obtain such services, on an ad hoc basis, from a service 
provider. Another altemative would be to establish (or join) a multi-party consortium where 
CIA T can jo in with one or severa! other CG Centers who need similar sorts of services. 
Regardless of the means by which these services are obtained, the services are essential for PP 
rights management. With these services CIA T can proactively use PP rights management to 
serve its programs and objectives. Without them it will be impossible to adequately function 
under the changing PP rights management rules. 
The final point (client capacity building, point 8) is an important step toward CIAT's overall 
goal. This involves, in part, the level of responsibility that CIA T chooses to take for the decisions 
and actions of its clients. lf CIA T sees such a responsibility, then it needs to set in place the 
process for client capacity building. Such capacity building must also involve developing 
adequate capacity within CIA T clients for them to understand contracts that the client may 
consummate either with CIAT or with another party. 
All of these issues may be more concems of the CIA T BOT and presumably of the CGIAR as a 
whole than of CIA T Management alone. The questions to be asked include: "Will CIA T supply 
improved germplasm, either transgenic or non-transgenic, to a client country without verification 
ofthe client's Proprietary Property rights management and/or biosafety management capability?" 
and, "Is providing capacity building in the areas ofProprietary Property rights management and 
biosafety CIAT's responsibility?" and, "What responsibility, if any, does CIAT have for the 
behavior ofits clients with regard to the client's use ofCIAT improved germplasm ifit contains 
Proprietary Property ofthird parties?" Providing answers to these and related questions will 
require varying levels of resource consumption and different levels of political issue resolution 
from clients as well as donors. 
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3.3.3 Agreements Management 
Recommendation 31: CIAT should harmonize its policies and procedures, and 
formalize its management, of its agreements 
l . Harmonization ofCIAT policies and procedures with terms ofnon-CIAT agreements 
both before and after negotiations. 
2. Establishment of a management database to record and report the terms of all CIAT and 
non-CIAT agreements and o'bligations contained therein. 
Initiating harmonizing changes in the first of these areas may be only a matter of redefining or 
expanding functions that are airead y in place. This is more an issue of experience, time and 
management than financia! resources. Therefore, the cost for this could be near negligible. 
The second area is crucial, particularly in light ofCIAT's strategy to expand its collaborations 
with non-CIA T entities. Its implementation is not without resource expenditure, both for the 
software and the establishment of such a database and for its day-to-day management and 
maintenance. There is also the cost ofharmonizing such a database with other CIAT databases 
(i.e. germplasm database, Proprietary Property database, etc.). However, not having sorne ready 
means of agreement management leaves unanswered many questions regarding CIAT's ability to 
manage its own Proprietary Property rights, especially as the number of agreements and their 
complexity increases. 
3.3.4 Biotech Component Management 
Recommendation 32: CIAT should ensure that certain terms used in agreements 
are clearly defmed and that the implications of standard 
defmitions are properly understood 
l . Distinguishing between "research only'' and "commercial" licenses. 
2. Harmonizing access to externa! biotechnology component sources. 
3. Clarifying to all, inside and outside CIAT, whether CIAT's release oftransgenic, 
improved germplasm constitutes commercial activity under statutory protection laws. 
The distinction between research and commercial licenses was relatively unimportant to CIA T 
when the principal mode for reaching its goal was traditional plant breeding without the use or 
incorporation of PP elements. The importance of understanding the distinctions changed 
dramatically with the expansion ofplant patenting and the seed industry introducing "bag tag" 
(licenses that a seed purchaser accepts when the bag is opened in the same way that a software 
purchaser accepts certain restrictions via a "shrink wrap" license) language. 
Nowhere is this more pronounced than with accessing biotechnology components. 
Misunderstanding the limitations of a research-only license may bring into question the ability to 
seek statutory protection on CIA T -made discoveries. Such misunderstanding may advance the 
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development of improved germplasm products that will be found to be in violation of the terms 
ofa material transfer agreement or other contract that CIAT has signed. For CIAT to manage PP 
rights these distinctions must be recognized, understood, acknowledged, and enforced. 
Not only is functioning within the limits of such agreements ethically required (accepting that it 
is unethical to enter into an agreement knowing in advance that one does not want to or cannot 
respect the terms ofthe agreement), it is a practica! consideration to prevent possible lawsuits. 
Ethical functioning is essential to CIAT's relationships with non-CIAT collaborators, as a model 
to its clients, and as a requirement from its donors. Further, because sorne plants or plant 
products that result from CIAT's improved, transgenic germplasm will reasonably enter the 
stream ofintemational trade, CIAT clients need to be readily aware ofPP rights issues and 
ramifications to their produce. 
3.3.5 Biotechnology Product Management 
Recommendation 33: CIAT must consider the implications ofvarious options 
related to Freedom-To-Operate and sbould establisb and 
communicate its position and mode of operation 
l. Determine at what level CIA T should inform its clients on FTO information related to 
its transgenic products. 
2. Establish intemal capacity to contribute to FTO reviews. 
Freedom-to-Operate: What is it? 
A FTO opinion is a risk management opinion. It is written by an attomey for the purpose of 
guiding an organization through or around perceived risks. These risks include aspects related to 
patents on products and processes that may influence an organization' s freedom to distribute and 
use the materials derived therefrom. Sometimes a FTO opinion may be broadened to cover 
biosafety and other regulatory aspects and obligations. FTO opinions will vary on a country-by-
country basis because most statutory protection is founded in nationallaw. Similar! y, FTO 
opinions are dynamic because patent status is dynamic. So FTO opinions must be regular! y 
reviewed and updated. 
An FTO opinion is just that; an opinion. It is nota definitive answer but only a patent attomey's 
opinion that if a dispute arises, the organization's behavior can be justified. Given currently 
popular crop irnprovement strategies, virtually no release of germplasm is without sorne degree 
of risk. As transgenic strategies begin to dominate crop improvement practices, both the risks 
and rewards of releasing improved germplasm can be expected to rise. 
Managing Freedom-to-Operate: 
As noted above, a FTO has to be conducted for a specific country in which a product is to be 
released. For CIA T, however, since its clients are diverse, the institute may wish to implement 
the following strategy: 
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• a certification ofwell known, easily-obtained Proprietary Property rights; 
• it may come with CIA T' s offer to help the recipient resol ve FTO issues. 
Alternately, CIAT may wish to apply different degrees ofFTO to different products, different 
components, on a client-by-client basis, or on a product-by-product basis, or based on other 
factors. Each option CIA T chooses has different consequences and it is imperative that CIA T 
considers the various options and implications. What is critica! is that its clients know what 
information they are being given and what their own options are. 
Essentially, CIA T has three options: 
l. ignore FTO 
2. conductor commission a selective or preliminary (or broad-brush) FTO 
3. conductor commission a comprehensive FTO on a global basis and/or tailor made for each 
country of release 
The three different options have different characteristics. Option 2 and 3 have the following: 
Option 3. Consequences of Applying Comprehensive FTO 
l . Highest level ofPP rights to the CIAT client. 
2. Requires significant resource commitment (internal and through outsourcing). 
3. Sorne funding sources may find a Comprehensive FTO inappropriate. 
4. Induce changes to CIAT's organizational structure requiring ata mínimum: 
• an Office of General Counsel; 
• an Office oflntellectual Property and Technology Transfer Management; 
• renewed emphasis on public information; 
• access to specialized databases and para-legal and legal services. 
5. Take measures to ensure that clients do not become dependent on CIAT's provision ofFTO. 
6. Could be provided as a cost-effective service (since CIAT would perform/outsource the FTO 
for the range ofNARS) to clients. 
7. Preclude any Proprietary Property rights concerns vis-a-vis the private sector. 
8. Draw resources away from serving the poorer of the poor unless additional resources can be 
leveraged through the process or unless improved product development becomes 
significantly more effective. 
Option 2: Consequences of Applying Se/ective FTO 
l . Delegate much PP rights management to client countries. (It should be recognized, however, 
that the majority ofNARS do not, at this stage and for the foreseeable future, have the 
capacity and resources to have a Comprehensive FTO executed or commissioned). 
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2. Limited use of CIA T resources. 
3. Constitutes a major challenge to non-CIAT research relationships once the products are ready 
to be transferred to and deployed by NARS. 
4. Collaboration with the private sector might be more sporadic. 
Possible Effects on CIA T with selective use of Comprehensive and Partía/ FTOs 
For CIA T, or more broadly for the client and donor community, either approach would require 
resolution ofthe issues listed below. It should be noted that whereas for the Comprehensive FTO 
approach, certain offices would need to be established by CIAT, for the Selective FTO approach, 
CIA T would still need a subset of the same activities but to a lesser degree. Such a blend of 
Comprehensive FTO and Selective FTO, on a project-by-project basis, a country-by-country 
basis, a component-by-component basis, or on sorne other basis, may be a feasible interim 
approach and may concurrently reduce sorne ofCIAT's resource requirements. At the same time, 
such a variable application may increase CIAT's administrative requirements. 
l. Office or Service ofGeneral Counsel for CIAT (interna! or externa!) whose duties would be 
to offer legal advice regarding: 
• negotiations with non-CIA T entities; 
• harmonization of CIA T -non-CIA T agreements with CIA T policies and procedures; 
• introduction of interna} protocols for release and recording of all classes of germplasm 
and related information held by CIA T; 
• receive all confidential statements of invention from CIA T researchers; 
• file and direct the statutory (patent, copyright, PVP, other) protection ofCIAT 
discoveries; 
• develop strategies toward enforcement of CIA T statutory protection rights; 
• respond to all challenges to CIA T regarding FTO rights matters; 
• direct CIA T litigation that may arise from enforcement of statutory protection rights; 
• other as required. 
2. Office or Service ofProprietary Property Management whose duties would be to: 
• serve as a single point of contact for all CIA T product releases through licensing or 
otherwise; 
• serve as a single point of contact for the receipt of all proprietary material and 
information that is received by CIA T researchers; 
• draft, with advice from the Office of General Counsel, all Proprietary Property rights 
agreements; 
• negotiate, with advice ofthe Office ofGeneral Counsel, all agreements with Non-CIAT 
entities; 
• compile, manage, and report to CIA T management regarding CIA T' s on-going 
Proprietary Property duties and responsibilities under the severa! agreements; 
• other as required. 
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3. Office or Service oflnformation whose duties would be to: 
• serve as a single point of contact for all CIA T press releases and other public statements 
including staff member publications, meeting attendance, and pos ter presentations; 
• implement and maintain a laboratory notebook policy across all CIA T locations; 
• manage guest visits, short-term staff appointments, etc.; 
• pro vide staff member training regarding those new policies and procedures that are 
required to harmonize obligations that CIA T may ha ve obtained through agreement with 
a Non-CIA T entity; 
• coordinate the responses to criticism by the public and/or a variety ofNGOs; 
• coordinate the responses and manage the interface with clients and donors dueto the 
changed relationships with CIA T clients resulting from giving different treatment to 
different client nations; 
• other as required. 
4. Introduction of adequate databases to report and coordinate CIA T' s accrued Proprietary 
Property rights and obligations. This would include databases relating to: 
• CIAT maintained germplasm, regardless of source; 
• agreements with Non-CIA T entities; 
• duties and obligations accruing from CIAT-Non-CIAT agreements; 
• patent and related scientific publications; 
• other as needed. 
3.3.6 Electronic Data Management 
See Recommendation 16: CIAT should establish procedures for receiving and sharing 
data from non-CIAT parties 
The PP rights for electronic information is very much in flux. They are more often regulated by a 
country's laws than by intemational treaty, and they may be sporadically enforced, particularly in 
developing countries. However, changes by way ofboth country laws and intemational treaties 
are fast being set in place. 
Many commonly practiced activities that may be violations oflaw (at least in sorne countries) 
are coming under increased scrutiny. Harmonization ofCIAT policies and procedures with PP 
rights management regarding electronic information acquisition and dissemination can be 
instituted for the cost of obtaining appropriate legal opinions and the re-writing of certain CIA T 
policies. To not re-write CIA T's policies and procedures could cost CIA T much credibility in the 
eyes of donors and non-CIAT collaborators. Finally, disregard for PP rights enforcement at 




Hannonization ofCIAT's policies and procedures with systematic and predictable PP rights 
management practices is not without cost, either financia! or political. However, failure to do so 
will, in the long term, adversely affect CIA T's relationship with its staff, its clients, its donors 
and non-CIA T collaborators. This CIA T can not afford to do. On the other hand, instituting these 
steps toward hannonization will put CIA Ton the proactive path that it has historically taken in 
its leadership role within the intemational research community. 
Re-writing policies is relatively inexpensive. Likewise, for enforcement ofthe revised policies. 
However, having a clear understanding of PP rights management is essential for strong 
relationships with all classes of non-CIA T entities. Strong relationships flow from honesty and 
consistency. Where agreements with a non-CIA T party were entered that do not consistently 
reflect CIA T policies and procedures, two choices exist: 
l . Change the agreement, or 
2. Change the policies and procedures. 
Re-negotiation of agreements prior to a dispute is typically preferable to waiting until a potential 
misunderstanding has grown to unrnanageable proportions. 
This Audit, ofa limited number ofCIAT projects, should be taken only as a starting point for 
continuing reviews of IPffP issues by CIA T staff and management. As the Audit report is 
integrated into CIAT's on-going activities, CIAT managers and staffmembers will develop the 
capacity to deal with the current recommended changes as well as proactively handle future 
IPffP issues as they arise. 
As with the garne of hockey, there are times when one or the other tearn seeks clarification of the 
rules of the game. Clarification and interpretation of the rules allows the activity to proceed 
toward the goal. 
CIAT's goal is not now and has never been in doubt. Effective IPffP management has the 
potential to make its endeavors more effective. In a certain way, CIA T has no option but to deal 
with the IP issues since the rules ha ve changed. The challenge for CIA T now is to continue on its 
path and reinforce its measures and activities to change, to better understand the new rules, and 
to capitalize on them for the benefit ofthe resource poor fanners it serves. 
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